WO2006068618A1 - New compounds - Google Patents

New compounds Download PDF

Info

Publication number
WO2006068618A1
WO2006068618A1 PCT/SE2005/002020 SE2005002020W WO2006068618A1 WO 2006068618 A1 WO2006068618 A1 WO 2006068618A1 SE 2005002020 W SE2005002020 W SE 2005002020W WO 2006068618 A1 WO2006068618 A1 WO 2006068618A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
thieno
pyridine
trifluoromethyl
amino
Prior art date
Application number
PCT/SE2005/002020
Other languages
French (fr)
Inventor
Andrew Griffin
Andrea Penwell
Miroslaw Tomaszewski
Simon Woo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to US11/721,637 priority Critical patent/US20080306107A1/en
Priority to JP2007548159A priority patent/JP2008525434A/en
Priority to EP05821044A priority patent/EP1833834A1/en
Publication of WO2006068618A1 publication Critical patent/WO2006068618A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to new compounds, to pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.
  • the present invention further relates to processes for the preparation of said compounds and to new intermediates used in the preparation thereof.
  • Pain sensation in mammals is due to the activation of the peripheral terminals of a special- ized population of sensory neurons known as nociceptors.
  • Capsaicin the active ingredient in hot peppers, produces sustained activation of nociceptors and also produces a dose-dependent pain sensation in humans.
  • Cloning of the vanilloid receptor 1 (VRl or TRPVl) demonstrated that VRl is the molecular target for capsaicin and its analogues. (Cate- rina,M.J., et al, et.al. Nature (1997) v.389 p 816-824).
  • VRl Functional studies using VRl indi- cate that it is also activated by noxious heat , tissue acidification) and other inflammatory mediators (Tominaga,M., etal. Neuron (1998) v.21, p.531-543). Expression of VRl is also regulated after peripheral nerve damage of the type that leads to neuropathic pain. These properties of VRl make it a highly relevant target for pain and for diseases involving inflammation. While agonists of the VRl receptor can act as analgesics through nociceptor destruction, the use of agonists, such as capsaicin and its analogues, is limited due to their pungency, neurotoxicity and induction of hypothermia. Instead, agents that block the activity of VRl should prove more useful.
  • Antagonists would maintain the analgesic properties, but avoid pungency and neurotoxicity side effects.
  • Compounds with VRl inhibitor activity are believed to be of potential use for the treatment and/or prophylaxis of disorders such as pain, especially that of inflammatory or traumatic origin such as arthritis, ischaemia, fibromyalgia, low back pain and post-operative pain (Walker et al., J Pharmacol Exp Ther. (2003) Jan; 304(l):56-62).
  • visceral pains such as chronic pelvic pain, cystitis, irritable bowel syndrome (IBS), pancreatitis and the like, as well as neuropathic pain such as sciatia, diabetic neuropathy, HIV neu- ropathy, multiple sclerosis, and the like (Walker et al ibid, J Pharmacol Exp Ther. (2003) Mar;304(3):940-8), are potential pain states that could be treated with VRl inhibiton.
  • These compounds are also believed to be potentially useful for inflammatory disorders like asthma, cough, inflammatory bowel disease (IBD) (Hwang, et al., Curr Opin Pharmacol (2002) Jun;2(3):235-42).
  • VRl blocker activity is also useful for itch and skin diseases like psoriasis and for gastro-esophageal reflux disease (GERD), emesis, urinary incontinence and hyperactive bladder (Yiangou et al BJU Int (2001) Jun;87(9):774-9, Szallasi, Am J Clin Pathol (2002) 118: 110-21).
  • VRl inhibitors are also of potential use for the treatment and/or prophylaxis of the effects of exposure to VRl activators like capsaicin or tear gas, acids or heat (Szallasi ibid).
  • VRl antagonists in Inflammatory Bowel Diseases (IBD) is further supported by the finding that primary sensory neuron denervation by subcutaneous administration of capsaicin to neonatal rats, -resulted in decreased levels of disease activity index (DAI), MPO and histological damage to the gut in DSS colitis model compared to control (N Ki- bara, et al. 5 Gut, 2003. 52: p: 713-719).
  • DAI disease activity index
  • MPO histological damage to the gut in DSS colitis model compared to control
  • N Ki- bara et al. 5 Gut, 2003. 52: p: 713-719
  • TRPVl antagonists attenuate macroscopic symptoms in DSS colitis model in mice (E. S. KIMBALL, et al., Neurogastroenterol Motil, 2004. 16: p. 1-8).
  • IBS Irritable Bowel Syndrome
  • Patients with faecal urgency and rectal hypersensitivity have increased levels of TRPVl expression in nerve fibres in muscle, submucosal and mucosal layers. This also correlates with increase sensitivity to heat and distension (C L H Chan, et al., THE LANCET, 2003. 361(Feb 1): p. 385-91).
  • Jejunal wide dynamic range (WDR) afferents show lower firing in response to pressure ex vivo in TRPVl-/- mice (Rong W, H.K., et al., J Physiol (Lond). 2004. 560: p. 867-881).
  • TRPVl TRPVl expression in peripheral nerves enervating the oesophageal epithelium
  • JYL 1421 Even if the TRPVl antagonist JYL 1421 only has minor effects of acid-induced excitation of esophageal afferents, an antagonist with a different profile has yet to be evaluated. Since TRPVl appears to play a role in mechanosensation, it is possible that antagonists may inhibit TLESRs 5 the main cause of gastroesophageal reflux.
  • VRl inhibitors may also be useful in the treatment of interstitial cystitis and pain related to interstitial cystitis.
  • Tornetta, B., et al. disclose the synthesis and spectral behavior of pyridothienoisothiazole and pyridothienopyrimidine derivatives. (Gazzetta Chimica Italiana (1978), 108(1-2), 57- 62)
  • the object of the present invention is to provide compounds) exhibiting an inhibitory ac- tivity at the vanilloid receptor 1 (VRl).
  • the present invention provides a compound of formula I
  • R 1 and R 2 are independently selected from H, NO 2 , NH 2 , halo, N(C 1-3 alkyl) 2 , C 1-3 alkyl, C 2- 3 alkenyl, C 2-3 alkynyl, C 1-3 haloalkyl, Cj, 3 haloalkylO, hydroxyC 1-3 alkyl, C 1-3 alkylOC 0-3 alkyl, C 1-3 alkylSC 0-3 alkyl and C 1-3 alkylNC 0-3 alkyl;
  • Y is NH 2 , NH(R 3 ), N(R 3 ) 2 , OH, OR 3 or NO 2 ;
  • R 3 is C ! . 3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, Ci-shaloalkyl, C 1-3 haloalkylO, hydroxyC 1-3 alkyl,
  • R 9 is H, C 1-6 alkyl, R 6 OC 0-6 alkyl, or C 5-1 oarylC o-6 alkyl;
  • X is bond, CR 6 R 7 , NR 6 R 7 or O; p is O, 1, 2, or 3; R 4 is bond, H, C ⁇ alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Q- ⁇ haloalkyl, C 1-6 haloalkylO, C 5- ioarylC 0 ' -6 alkyl, C5 -1 oheteroarylC 0 . 6 alkyl, C 3-15 cycloalkylC 0-6 alkyl, C 3-15 heterocycloalkylC 0 .
  • R 5 is H,- OH, oxy, NO 2 , NH 2 , halo, N(C 1-3 alkyl) 2 , C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C 1 . 3 haloalkyl, C 1-3 haloalkylO, hydroxyC 1-3 alkyl, R 6 OC 0-6 alkyl, R 6 SC 0-6 alkyl, R ⁇ Co ⁇ alkyl,
  • R 6 , R 7 and R 8 are independently selected from H, C 1-6 alkyl and C 5 -ioarylC o-6 alkyl; or X and R 6 form a 4, 5, 6 or 7 membered ring; and n is 0, 1, 2, 3, 4, 5, 6 or 7; or salts, solvates or solvated salts thereof.
  • R 1 is Ci -2 alkyl. In another embodiment R 1 is methyl, ethyl, n-propyl or i-propyl.
  • R 2 is C 1-2 haloalkyl, whereby halo is fluoro or bromo.
  • R 2 is fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl or difluoroethyl. In yet another embodiment R 2 is trifluoromethyl.
  • Y is NH 2 or NH(R 3 ), wherein R 3 is C 1-3 alkyl. In another embodiment
  • Y is NH 2 .
  • R 9 is H or C 1-6 alkyl. In yet a further embodiment R 9 is H. In one embodiment R 9 is methyl, ethyl, n-propyl or i-propyl.
  • X is a bond.
  • X is CR 6 R 7 , whereby R 6 and R 7 may the same or different and selected from H, C 1-3 alkyl and C 5-
  • X is NR 6 R 7 and O. In another embodiment X is methyl. In yet another embodiment R 6 and X form together phenyl.
  • R 4 is C 5-lo arylC o-6 alkyl or C 1-6 alkyl. In a further embodiment R 4 is C 5 . 6 aryl.
  • R 4 is phenyl.
  • R 5 is H 5 halo, C 1-3 alkyl, C ⁇ 3 haloalkyl or R 6 OC 0-6 alkyl.
  • R 5 is H, chloro or fluoro. In a further embodiment R 5 is C 1-3 alkyl. In yet another embodiment R 5 is methyl, ethyl, n- propyl or i-propyl.
  • R 5 is Ci -2 haloalkyl, whereby halo is fluoro or bromo.
  • R 5 is fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl or di- fluoroethyl. In yet another embodiment R 5 is trifluoromethyl. In another embodiment R 5 is R 6 OCo -6 alkyl, whereby R 6 is Cj. 3 alkyl. In a further embodiment R 6 is methoxy, ethoxy or propoxy.
  • p is 1, 2, or 3, with the proviso that the compound is not 3-amino-6- methyl-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid benzylamide.
  • a further embodiment of the invention relates to the compound selected from the group consisting of i o 3 -amino-6-methyl-iV-(3-pheny lpropyl)-4-(trifJ.uoromethyl)thieno [2,3 -6]pyridine-2-carbox- amide,
  • a yet further embodiment of the invention relates to the compound selected from the group consisting of
  • 3-amino-N-(2,3-dihydro-l,4-benzodioxin-2-ylmethyl)-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide is 3-amino-N- ⁇ 2-[4-(ethyloxy)phenyl]ethyl ⁇ -6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide
  • Yet another embodiment of the invention relates to the compounds selected from the group consisting of 3-amino-6-methyl-N-[(2S)-2-phenylpropyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
  • alkyl includes both straight and branched chain alkyl groups and may be, but are not limited to methyl, ethyl, n-propyl, i- propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl or i-hexyl, t-hexyl.
  • C 1-3 alkyl having 1 to 3 carbon atoms and may be methyl, ethyl, n-propyl, i-propyl or tert-butyl.
  • 'C 0 ' means a bond or does not excist.
  • R 1 is C o alkyl
  • R 1 is a bond and "arylC o alkyl” is equivalent with “aryl”
  • C 2 alkylOC 0 alkyl is equivalent with “C 2 alkylO”.
  • alkenyl includes both straight and branched chain alkenyl groups.
  • C 2 - 6 alkenyl having 2 to 6 carbon atoms and one or two double bonds, may be, but is not limited to vinyl, allyl, propenyl, butenyl, cro- tyl, pentenyl, or hexenyl, and a butenyl group may for example be buten-2-yl, buten-3-yl or buten-4-yl.
  • alkynyl includes both straight and branched chain alkynyl groups.
  • C 2 - 6 alkynyl having 2 to 6 carbon atoms and one or two trippel bonds, may be, but is not limited to etynyl, propargyl, pentynyl or hexynyl and a butynyl group may for example be butyn-3-yl or butyn-4-yl.
  • cycloalkyl refers to an optionally substituted, saturated cyclic hydrocarbon ring system.
  • C 3-7 CyClOaUCyI may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • heterocycloalkyl refers to a 3- to 7-membered, non-aromatic, partially or completely saturated hydrocarbon group, which contains one ring and at least one heteroatom.
  • heterocycle include, but are not limited to pyrrolidinyl, pyrrolidonyl, piperidinyl, piperazinyl, morpholinyl, oxa- zolyl, 2-oxazolidonyl or tetrahydrofuranyl.
  • aryl refers to an optionally substituted monocyclic or bicyclic hydrocarbon unsaturated aromatic ring system. Examples of “aryl” may be, but are not limited to phenyl and naphthyl.
  • heteroaryl refers to an optionally substituted monocyclic or bicyclic unsaturated aromatic ring system containing at least one heteroatom selected independently form N, O or S.
  • heteroaryl may be, but are not limited to pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thia- zolyl, pyrazolyl, benzofuryl, indolyl, isoindolyl, benzimidazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, tetrazolyl, triazolyl or oxazolyl.
  • arylalkyl and “heteroarylalkyl” refer to a substiruent that is attached via the alkyl group to an aryl or heteroaryl group.
  • the term "4, 5, 6 or 7 membered ring” includes aryl, heteroaryl, cycloalkyl and heterocycloalkyl as defined above.
  • haloalkyl means an alkyl group as defined above, which is substituted with halo as defined above.
  • d- ⁇ haloalkyl may include, but is not limited to fluoromethyl, difluoromethyl, trifluoromethyl, fluoro- ethyl, difluoroethyl or bromopropyl.
  • Ci -6 haloalkylO may include, but is not limited to fluoromethoxy, difluoromethoxy, trifluoromethoxy, fluoroethoxy or difluoroeth- oxy.
  • the present invention relates to the compounds of formula I as hereinbefore defined as well as to the salts, solvates or solvated salts thereof.
  • Salts for use in pharmaceutical formulations will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I.
  • a suitable pharmaceutically acceptable salt of the compounds of the invention is, for ex- ample, an acid-addition salt, for example a salt with an inorganic or organic acid.
  • a suitable pharmaceutically acceptable salt of the compounds of the invention is an alkali metal salt, an alkaline earth metal salt or a salt with an organic base.
  • Other pharmaceutically acceptable salts and methods of preparing these salts may be found in, for example, Remington's Pharmaceutical Sciences (18 th Edition, Mack Publishing Co.).
  • Some compounds of formula I may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such op- tical, diastereoisomeric ar.d geometric isomers.
  • the invention also relates io any and all tautomeric forms of the compounds of formula I.
  • the compounds according to the present invention are useful in therapy.
  • the compounds may be used to produce an inhibitory effect of VRl in mammals, including man.
  • VRl are highly expressed the peripheral nervous system and in other tissues. Thus, it is expected that the compounds of the invention are well suited for the treatment of VRl me- diated disorders.
  • the compounds of formula I are expected to be suitable for the treatment of acute and chronic pain, acute and chronic neuropathic pain and acute and chronic inflammatory pain.
  • disorders may be selected from the group comprising arthritis, rheuma- toid arthritis, spondylitis and gout, fibromyalgia, low back pain and sciatica, post-operative pain, cancer pain, migraine and tension headache, visceral pains like chronic pelvic pain, cystitis, including interstitial cystitis, pancreatitis, renal and biliary colic, menstruation as- sociated pain, pain related to ischeamic and angina, neuropathic pain disorders such as diabetic neuropathy, HIV neuropathy, chemotherapy induced neuropathies, post-herpetic neuralgia, post traumatic neuralgia and complex regional syndrome as well as itch.
  • GSD gastroesophageal reflux disease
  • FGD functional gastrointestinal disorders
  • IBS irritable bowel syndrome
  • IBS irritable bowel syndrome
  • FD functional dyspepsia
  • disorders are overactive bladder (“OAB”), a term for a syndrome that encompasses urge incontinence, urgency and frequency.
  • Compounds of the invention may alleviate urinary incontinence ("UI") the involuntary loss of urine that results from an inability of the bladder to retain urine as a consequence of either urge (urge incontinence), or physical or mental stress (stress incontinence).
  • UI urinary incontinence
  • Other relevant disorders may be psoriasis, and emesis.
  • the VRl inhibitor(s) for respiratory use may be administrated by either an oral or inhaled route.
  • the respiratory disease may be an acute and chronic illness and may be related to infection(s) and/or exposure to environmental pollution and/or irritants.
  • the compounds of formula I may also be used as antitoxin to treat (over-) exposure to VRl activators like capsaicin, tear gas, acids or heat. Regarding heat, there is a potential use for VRl antagonists in (sun-)burn induced pain, or inflammatory pain resulting from burn in- juries.
  • the compounds may further be used for treatment of tolerance to VRl activators.
  • One embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, in therapy.
  • Another embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of VRl mediated disorders.
  • a further embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of acute and chronic pain.
  • Yet another embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of acute and chronic neuropathic pain.
  • Yet a further embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of acute and chronic inflammatory pain.
  • One embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of arthritis, rheumatoid arthritis, spondylitis and gout, fibromyalgia, low back pain and sciatica, post-operative pain, cancer pain, migraine and tension headache, visceral pains like chronic pelvic pain, cystitis, including interstitial cys- titis, pancreatitis, renal and biliary colic, menstruation associated pain, pain related to ischeamic and angina, neuropathic pain disorders such as diabetic neuropathy, HIV neuropathy, chemotherapy induced neuropathies, post-herpetic neuralgia, post traumatic neuralgia and complex regional syndrome as well as itch.
  • Another embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of gastroesophageal reflux disease, functional gastrointestinal disorders, irritable bowel syndrome, irritable bowel syndrome and functional dyspepsia.
  • a further embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of overactive bladder.
  • Yet a further embodiment of the invention relates to the use of the compound of formula I as hereinbefore defined, for the treatment of respiratory diseases selected from the group comprising of cough, asthma, chronic obstructive lung disease and emphysema, lung fibrosis and interstitial lung disease.
  • respiratory diseases selected from the group comprising of cough, asthma, chronic obstructive lung disease and emphysema, lung fibrosis and interstitial lung disease.
  • One embodiment of the invention relates to the use of the compound of formula I as hereinbefore defined, in the manufacture of a medicament for treatment of VRl mediated disorders and for treatment of acute and chronic pain, acute and chronic neuropathic pain and acute and chronic inflammatory pain, and respiratory diseases, and any other disorder mentioned above.
  • Another embodiment of the invention relates to a method of treatment of VRl mediated disorders and acute and chronic pain, acute and chronic neuropathic pain and acute and chronic inflammatory pain, and respiratory diseases, and any other disorder mentioned above, comprising administrering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compounds -of formula I, as hereinbefore defined.
  • a further embodiment of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I as hereinbefore defined, for use in treatment of VRl mediated disorders and for treatment of acute and chronic pain, acute and chronic neuropathic pain and acute and chronic inflammatory pain, and respiratory diseases, and any other disorder mentioned above.
  • the term “therapy” and “treatment” includes prevention and prophylaxis, unless there are specific indications to the contrary.
  • the terms “treat'7'therapeutic” and “therapeutically” should be construed accordingly.
  • inhibitor and “antagonist” mean a compound that by any means, partly or completely, blocks the transduction pathway lead- ing to the production of a response by the ligand.
  • disorder means any condition and disease associated with vanilloid receptor activity.
  • the compounds of the invention are also useful as pharmacological tools in the develop- ment and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of VRl related activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutics agents.
  • a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound of formula I, or salts, solvates or solvated salts thereof, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.
  • the composition may be in a form suitable for oral administration, for example as a- tablet, pill, syrup, powder, granule or capsule, for parenteral injection (including intravenous, . subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration e.g. as an ointment, patch or cream or for rectal ad- 5 ministration e.g. as a suppository.
  • parenteral injection including intravenous, . subcutaneous, intramuscular, intravascular or infusion
  • a sterile solution e.g. as an ointment, patch or cream
  • rectal ad- 5 ministration e.g. as a suppository.
  • compositions may be prepared in a conventional manner using one or more conventional excipients, pharmaceutical acceptable diluents and/or inert carriers.
  • Suitable daily doses of the compounds of formula I in the treatment of a mammal, including man, are approximately 0.01 to 250 mg/kg bodyweight at peroral administration and o about 0.001 to 250 mg/kg bodyweight at parenteral administration.
  • the typical daily dose of the active ingredient varies within a wide range and will depend on various factors such as the relevant indication, severity of the illness being treated, the route of administration, the age, weight and sex of the patient and the particular compound being used, and may be determined by a physician. 5
  • compositions may be obtained by conventional procedures well known in the pharmaceutical art.
  • heterocyclic Chemistry J. A. Joule, K. Mills, G. F. Smith, 3 rd ed. Chapman and Hall (1995), p. 189-224 and "Heterocyclic Chemistry", T. L. Gilchrist, 2 nd ed. Longman Scientific and Technical (1992), p. 248-282.
  • room temperature and “ambient temperature” shall mean, unless otherwise specified, a temperature between 16 and 25 °C.
  • One embodiment of the invention relates to processes for the preparation of the compound of formula I according to scheme 1, 2, 3, 4, 5, or 6; wherein R 1 to R 9 , X, n and p are as de ⁇ fined above;
  • One embodiment of the invention relates to the compounds 4-(trifluoromethyl)nicotinonitrile 1 -oxide, i o 2-chloro-4-(trifluoromethyl)nicotinonitrile,
  • the com- bined organic phases were washed with brine (2x), and then dried .over Na 2 SO 4 , filtered, and concentrated in vacuo.
  • the crude product was purified by silica gel chromatography eluting with 5:1 CH 2 Cl 2 :EtO Ac, followed by a second purification eluting with 3:1 hex- anes:EtOAc, to provide the title compound as a yellow solid (0.211 g, 47%).
  • %yridine-2-carboxylic acid (0.150 g, 0.54 mmol), HATU (0.310 g, 0.81 mmol), DIPEA s (0.24 mL, 1.38 mmol), and (R)-(+)- ⁇ -methylphenethylamine (110 ⁇ L, 0.77 mmol) were combined.
  • Transfected CHO cells stably expessing hVRl (15,000 cells/well) are seeded in 50 ul media in a black clear bottom 384 plate (Greiner) and grown in a humidified incubator (37°C, 2% CO 2 ), 24-30 hours prior to experiment.
  • the media is removed from the cell plate by inversion and 2 ⁇ M Fluo-4 is added using a multidrop (Labsy stems). Following the 40 minutes dye incubation in the dark at 37°C and 2% CO 2 , the extracellular dye present is washed away using an EMBLA (Scatron), leaving the cells in 40ul of assay buffer (1 X BBSS, 10 mM D-Glucose, 1 mM CaCl 2 , 10 mM HEPES, 10 X 7.5% NaHCO 3 and 2.5 mM Probenecid).
  • assay buffer (1 X BBSS, 10 mM D-Glucose, 1 mM CaCl 2 , 10 mM HEPES, 10 X 7.5% NaHCO 3 and 2.5 mM Probenecid).
  • the fluorescence is read using FLlPR filter 1 (em 520-545 nM).
  • a cellular baseline recording is taken for 30 seconds, followed by a 20 ⁇ l addition of 10, titrated half-log concentrations of the test compound, yielding cellular concentration ranging from 3 ⁇ M to 0.1 nM.
  • Data is collected every 2 seconds for a further 5 minutes prior to the addition of a VRl agonist solution: either 50 nM solution of capsaicin or MES (2-[N-mor- pholino] ethanesulfonic acid) buffer (pH 5.2), by the FLIPR pipettor.
  • the FLIPR continues to collect data for a further 4 minutes.
  • Typical ⁇ C50 values as measured in the assays described above are 1 ⁇ M or less.
  • the IC 50 is below 750 nM.
  • the IC 50 is below 150 nM.
  • the IC 50 is below 10 nM.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to new compounds of formula (I) wherein R1 to R9, X, p and n are defined as in claim 1, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

Description

NEW COMPOUNDS .
FIELD OF THE INVENTION
The present invention relates to new compounds, to pharmaceutical compositions containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates used in the preparation thereof.
BACKGROUND OF THE INVENTION
Pain sensation in mammals is due to the activation of the peripheral terminals of a special- ized population of sensory neurons known as nociceptors. Capsaicin, the active ingredient in hot peppers, produces sustained activation of nociceptors and also produces a dose-dependent pain sensation in humans. Cloning of the vanilloid receptor 1 (VRl or TRPVl) demonstrated that VRl is the molecular target for capsaicin and its analogues. (Cate- rina,M.J., et al, et.al. Nature (1997) v.389 p 816-824). Functional studies using VRl indi- cate that it is also activated by noxious heat , tissue acidification) and other inflammatory mediators (Tominaga,M., etal. Neuron (1998) v.21, p.531-543). Expression of VRl is also regulated after peripheral nerve damage of the type that leads to neuropathic pain. These properties of VRl make it a highly relevant target for pain and for diseases involving inflammation. While agonists of the VRl receptor can act as analgesics through nociceptor destruction, the use of agonists, such as capsaicin and its analogues, is limited due to their pungency, neurotoxicity and induction of hypothermia. Instead, agents that block the activity of VRl should prove more useful. Antagonists would maintain the analgesic properties, but avoid pungency and neurotoxicity side effects. Compounds with VRl inhibitor activity are believed to be of potential use for the treatment and/or prophylaxis of disorders such as pain, especially that of inflammatory or traumatic origin such as arthritis, ischaemia, fibromyalgia, low back pain and post-operative pain (Walker et al., J Pharmacol Exp Ther. (2003) Jan; 304(l):56-62). In addition to this visceral pains such as chronic pelvic pain, cystitis, irritable bowel syndrome (IBS), pancreatitis and the like, as well as neuropathic pain such as sciatia, diabetic neuropathy, HIV neu- ropathy, multiple sclerosis, and the like (Walker et al ibid, J Pharmacol Exp Ther. (2003) Mar;304(3):940-8), are potential pain states that could be treated with VRl inhibiton. These compounds are also believed to be potentially useful for inflammatory disorders like asthma, cough, inflammatory bowel disease (IBD) (Hwang, et al., Curr Opin Pharmacol (2002) Jun;2(3):235-42). Compounds with VRl blocker activity are also useful for itch and skin diseases like psoriasis and for gastro-esophageal reflux disease (GERD), emesis, urinary incontinence and hyperactive bladder (Yiangou et al BJU Int (2001) Jun;87(9):774-9, Szallasi, Am J Clin Pathol (2002) 118: 110-21). VRl inhibitors are also of potential use for the treatment and/or prophylaxis of the effects of exposure to VRl activators like capsaicin or tear gas, acids or heat (Szallasi ibid).
The role for VRl antagonists in Inflammatory Bowel Diseases (IBD) is further supported by the finding that primary sensory neuron denervation by subcutaneous administration of capsaicin to neonatal rats, -resulted in decreased levels of disease activity index (DAI), MPO and histological damage to the gut in DSS colitis model compared to control (N Ki- bara, et al.5 Gut, 2003. 52: p: 713-719). TRPVl antagonists attenuate macroscopic symptoms in DSS colitis model in mice (E. S. KIMBALL, et al., Neurogastroenterol Motil, 2004. 16: p. 1-8). The potential for a role for VRl antagonists in Irritable Bowel Syndrome (IBS) has been described. Patients with faecal urgency and rectal hypersensitivity have increased levels of TRPVl expression in nerve fibres in muscle, submucosal and mucosal layers. This also correlates with increase sensitivity to heat and distension (C L H Chan, et al., THE LANCET, 2003. 361(Feb 1): p. 385-91). Jejunal wide dynamic range (WDR) afferents show lower firing in response to pressure ex vivo in TRPVl-/- mice (Rong W, H.K., et al., J Physiol (Lond). 2004. 560: p. 867-881). The visceromotor responses to jejunal and colorectal distension in rat are affected by a TRPVl antagonist using both ramp and phasic distensions (Winchester, EMG response to jejunal and colorectal distension in rat are affected by a TRPVl antagonist in both ramp and phasic distensions. DDW abstract, 2004). Capsaicin applied to the ileum induce pain and mechanical hyperalgesia in human experimental model (Asbjørn Mohr Drewes, et al., Pain, 2003. 104: p. 333-341). A role in Gastroesophageal Reflux Disease (GERD) for VRl antagonists has been mentioned in the literature. Patients with oesophagitis have increased levels of TRPVl expression in peripheral nerves enervating the oesophageal epithelium (P. J. Matthews, et al., European J. of Gastroenterology & Hepatology, 2004. 16: p. 897-902). Even if the TRPVl antagonist JYL 1421 only has minor effects of acid-induced excitation of esophageal afferents, an antagonist with a different profile has yet to be evaluated. Since TRPVl appears to play a role in mechanosensation, it is possible that antagonists may inhibit TLESRs5 the main cause of gastroesophageal reflux.
A further portential use relates to the treatment of tolerance to VRl activators. VRl inhibitors may also be useful in the treatment of interstitial cystitis and pain related to interstitial cystitis.
Prior art
Guerrera, et al., describe the synthesis and antifungal activity of pyrido[3',2':4,5]thieno[3,2-d]-l,2,3-triazine derivatives. (Farmaco (1993), 48(12), 1725- 33).
Dunn, A., et al., disclose a nucleophilic displacements m pyridine rings. (J. of Heterocyclic Chemistry (1987), 24(1), 85-9)
Tornetta, B., et al., disclose the synthesis and spectral behavior of pyridothienoisothiazole and pyridothienopyrimidine derivatives. (Gazzetta Chimica Italiana (1978), 108(1-2), 57- 62)
Guerrera, F.; et al., further discloses the synthesis of 3-arninόthieno[2,3-b]pyridine derivatives, pyridothienopyrimidine and pyridothienoisothiazole derivatives. (Chimica e l'lndus- tria (Milan, Italy), (1976), 58(6), 451-2.) Schneller, S., et al., describe fused thieno[3,2-d]-v-triazine-4(3H)-ones in Heterocycles (1975), 3(2), 135-8.
DETADLED DESCRIPTION OF THE INVENTION
The object of the present invention is to provide compounds) exhibiting an inhibitory ac- tivity at the vanilloid receptor 1 (VRl).
The present invention provides a compound of formula I
Figure imgf000004_0001
R1 and R2 are independently selected from H, NO2, NH2, halo, N(C1-3alkyl)2, C1-3alkyl, C2- 3alkenyl, C2-3alkynyl, C1-3haloalkyl, Cj,3haloalkylO, hydroxyC1-3alkyl, C1-3alkylOC0-3alkyl, C1-3alkylSC0-3alkyl and C1-3alkylNC0-3alkyl;
Y is NH2, NH(R3), N(R3)2, OH, OR3 or NO2; R3 is C!.3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-shaloalkyl, C1-3haloalkylO, hydroxyC1-3alkyl,
Ci-3alkylOC0-3alkyl, C1-3alkylSC0-3alkyl or C1-3alkylNC0-3alkyl;
R9 is H, C1-6alkyl, R6OC0-6alkyl, or C5-1oarylCo-6alkyl;
X is bond, CR6R7, NR6R7 or O; p is O, 1, 2, or 3; R4 is bond, H, C^alkyl, C2-6alkenyl, C2-6alkynyl, Q-δhaloalkyl, C1-6haloalkylO, C5- ioarylC0'-6alkyl, C5-1oheteroarylC0.6alkyl, C3-15cycloalkylC0-6alkyl, C3-15heterocycloalkylC0.
6alkyl, R6OC0-6alkyl, R6SC0-6alkyl or R^Co^alkyl, COOR6, R6COR7, R6CO2,
R6CONR7R8, R6NR7COCo-6alkyl, R6SO2R7 or R6SOR7R8;
R5 is H,- OH, oxy, NO2, NH2, halo, N(C1-3alkyl)2, C1-3alkyl, C2-3alkenyl, C2-3alkynyl, C1. 3haloalkyl, C1-3haloalkylO, hydroxyC1-3alkyl, R6OC0-6alkyl, R6SC0-6alkyl, R^Co^alkyl,
C5-i0arylOC0-6alkyr, C5-10heteroarylOC0-6alkyl, C3-10cycloalkylOC0-6alkyl, R6COO,
R6COR7, R6CO2, R6CONR7R8, R6NR7COC0-6alkyl or R6SO2R7 or R6SOR7R8;
R6, R7 and R8 are independently selected from H, C1-6alkyl and C5-ioarylCo-6alkyl; or X and R6 form a 4, 5, 6 or 7 membered ring; and n is 0, 1, 2, 3, 4, 5, 6 or 7; or salts, solvates or solvated salts thereof.
In one embodiment of the invention R1 is Ci-2alkyl. In another embodiment R1 is methyl, ethyl, n-propyl or i-propyl.
In a further embodiment R2 is C1-2haloalkyl, whereby halo is fluoro or bromo. In one embodiment R2 is fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl or difluoroethyl. In yet another embodiment R2 is trifluoromethyl.
In one embodiment Y is NH2 or NH(R3), wherein R3 is C1-3alkyl. In another embodiment
Y is NH2. In yet another embodiment R9 is H or C1-6alkyl. In yet a further embodiment R9 is H. In one embodiment R9 is methyl, ethyl, n-propyl or i-propyl.
In a further embodiment of the invention X is a bond. In another embodiment X is CR6R7, whereby R6 and R7 may the same or different and selected from H, C1-3alkyl and C5-
10arylC0-3alkyl. In one embodiment X is NR6R7 and O. In another embodiment X is methyl. In yet another embodiment R6 and X form together phenyl.
In one embodiment R4 is C5-loarylCo-6alkyl or C1-6alkyl. In a further embodiment R4 is C5. 6aryl.
In yet a further embodiment R4 is phenyl. '
In one embodiment R5 is H5 halo, C1-3alkyl, Cμ3haloalkyl or R6OC0-6alkyl.
In another embodiment R5 is H, chloro or fluoro. In a further embodiment R5 is C1-3alkyl. In yet another embodiment R5 is methyl, ethyl, n- propyl or i-propyl.
In yet a further embodiment R5 is Ci-2haloalkyl, whereby halo is fluoro or bromo.
In one embodiment R5 is fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl or di- fluoroethyl. In yet another embodiment R5 is trifluoromethyl. In another embodiment R5 is R6OCo-6alkyl, whereby R6 is Cj.3alkyl. In a further embodiment R6 is methoxy, ethoxy or propoxy.
In one embodiment p is 1, 2, or 3, with the proviso that the compound is not 3-amino-6- methyl-4-trifluoromethyl-thieno[2,3-b]pyridine-2-carboxylic acid benzylamide.
Another embodiment of the invention relates to the compound selected from the group consisting of
3-amino-6-methyl-iV-(3-phenylpropyl)-4-(trifluoromethyl)thieno[2,3-ό]pyridine-2-carbox- amide, 3-amino-6-methyl-iV-[2-(4-methylphenyl)ethyl]-4-(trifluoromethyl)thieno[2,3--j]pyridine- 2-carboxamide, 3-amino-6-methyl-N-[2-(2-methylphenyl)ethyl]-4-(ixifluoromethyl)thieno[2,3-6]pyridme-
2-carboxamide,
3-amino-6-methyl-iV-(2-phenylpropyl)-4-(trifluoromethyl)t]iieno[2,3-ό]pyridine-2-carbox- amide, 3-aimno-N,6-dimethyl-N-(2-phenyle1hyl)-4-(trifluoromethyl)tliieno[2,3-&]pyridine-2-car- boxamide,
3-amino-N-[2-(2-methoxyphenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-
Z>]pyridine-2-carboxamide,
3-amino-N-(2,2-diphenylethyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-έ]pyridine-2-car- boxamide,
3 -amino-iV-[2-(3 -fluorophenyl)ethyl] -6-methyl-4-(trifluoromethyl)thieno [2,3 -ό]pyridine-.2~ carboxamide, 3-amino-N-[2-(3,4-dichlorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-
6]pyridine-2-carboxamide, 3 -amino-6-methyl-4-(trifluoromethy I)-N- {2- [3 -(trifluoromethyl)phenyl] ethyl} thieno [2,3 -
6]pyridine-2-carboxamide,
3-amino-6-methyl-Ν-{2-[3-(metb.yloxy)phenyl]ethyl}-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-6-methyl-N-[2-(2-thienyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-car- boxamide,
3-amino-N-[2-(2,6-dichlorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-[2-(2-fluorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide, 3-amino-6-methyl-N-[2-(phenyloxy)ethyl]-4-(txifluoromethyl)thieno[2,3-b]pyridine-2-car- boxamide,
3-amino-N-(2,3-dihydro-l,4-benzodioxin-2-ylmethyl)-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N-{2-[4-(ethyloxy)phenyl]ethyl}-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-6-metb.yl-N-(4-methylcyclob.exyl)-4-(trifluoromethyl)thieno[233-b]pyridine-2- carboxamide, 3-amino-6-methyl-N-{2-[2-(phenyloxy)phenyl]ethyl}-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-6-methyl-N-{[5-methyl-2-(trifluoromethyl)-3-furanyl]methyl}-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide, 14-dimethylethyl 4-({[3-amino-6-methyl-4-(trifluoronietliyl)thieno[2,3-b]pyridin-2- yljcarbonyl} amino)- 1 -piperidinecarboxylate,
3-amino-N-{[3-fluoro-5-(triflιιoromethyl)phenyl]methyl}-6-metliyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-ainino-6-methyl-4-(trifluoromethyl)-N-{[3-(1xifluorometiiyl)phenyl]methyl}thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-(3,3-dimethylbu1yl)-6-metliyl-4-(triπύ.oromethyl)tb.ieno[253-b]pyridine-2-car- boxamide,
3-amino-6-methyl-4-(trifluoromethyl)-N-({3-[(triiiuoro- methyl)oxy]phenyl}methyl)thieno[2,3-b]pyridme-2-carboxamide, 3-amino-N-{2-[4-(l,l-dimethylethyl)phenyl]ethyl}-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-6-methyl-N-{3-[methyl(phenyl)amino]propyl}-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-[(3,5-dimethylphenyl)methyl]-6-methyl-4-(txifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-(cyclohexylmethyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-car- boxamide,
3-amino-N-butyl-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N-[2-(234-dichlorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-cyclohexyl-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N-[(5-fluoro-2-methylphenyl)methyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-[l-(4-fluorophenyl)e&yl]-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-aimno-6-methyl-N-(2-methylpropyl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carbox- amide, 3-amino-N-[(6-fluoro-4H-l,3-benzodioxin-8-yl)methyl]-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N,6-dimethyl-4-(trifluoromethyl)-N-{[3-(trifluoro- methyl)phenyl]methyl}thieno[2,3-b]pyridine-2-carboxamide, 3-amino-N-(2,3-dihydro-l-benzofuran-5-ylmethyl)-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-6-methyl-N-[2-(2-pyridinyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-amino-6-methyl-N-[2-(4-pyridinyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-araino-6-methyl-iV'-[(2S)-2-pb.enylpropyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine--2- carboxamide,
3-amino~6-methyl-iV-[(2R)-2-phenylpropyl]-4-(trifluorometliyl)thieno[2,3-b]pyridine-2- carboxamide, 3-amino-7V-[(2)2)-2-hydroxy-2-phenylethyl]-6-methyl-4-(triiluoromethyl)thieno[2,3- δjpyridme-2-carboxamide,
3-aimno-iV-[(2iS)-2-hydroxy-2-phenylethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-
Z?]pyridine-2-carboxamide,
3-amino-iV-(2-hydroxy-2-phenylpropyl)-6-methyl-4-(trifluorometb.yl)thieno[2,3- 5]pyridine-2-carboxamide,
3-amino-N-[2-(2-fΛiryl)ethyl]-6-rnethyl-4-(trifluoromethyl)thieno[253-b]pyridine-2-carbox- amide,
3-amino-N-[2-(4-fluorophenyl)ethyl]-6-meth.yl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide, 3-amino-iV-(2-cyclohexylethyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-δ]pyridme-2-car- boxamide,
3-amino-6-methyl-N-(trans-4-methylcyclohexyl)-4-(trifluorometliyl)tliieno[2,3-δ]pyridine-
2-carboxamide,
6-methyl-3-(methylamino)-N-(2-phenylethyl)-4-(trifluoromethyl)tliieno[2,3-b]pyridine-2- carboxamide,
3-(dimemylamino)-6-methyl-N-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-έ]pyridine-
2-carboxamide, 3-amino-N-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide, 3-amino-N-[2-(4-methylphenyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carbox- amide, and
3-amino-N-[2-(3-fluorophenyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carbox- 5 amide, or salts, solvates or solvated salts thereof.
A further embodiment of the invention relates to the compound selected from the group consisting of i o 3 -amino-6-methyl-iV-(3-pheny lpropyl)-4-(trifJ.uoromethyl)thieno [2,3 -6]pyridine-2-carbox- amide,
3-amino-6-methyl-iV-[2-(4-methylpheny]')etliyl]-4-(trifluoromethyl)thieno[2,3-έ]pyridine-
2-carboxamide,
3-amino-6-methyl-iV-[2-(2-methylplienyl)ethylJ-4-(trifluoromethyl)thieno[2,3-δ]pyridine- is 2-carboxamide,
3-amino-6-methyl-N-(2-phenylpropyl)-4-(trifluofomethyl)thieno[2,3-έ]pyridine-2-carbox- amide,
3-amino-iV,6-dimethyl-N-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-6]pyridme-2-car- boxamide, 20 3-amino-iV-[2-(2-methoxyphenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- έ]pyridine-2-carboxamide,
3-amino-N-(2,2-diphenylethyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-δ]pyridine-2-car- boxamide,
3-amino-iV-[2-(3-fluorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-Z>]pyridine-2- 5 carboxamide,
3-amino-N-[2-(3,4-dichlorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- έ]pyridine-2-carboxamide,
3-anαino-6-methyl-4-(trifluoromethyl)-iV-{2-[3-(trifluoromethyl)phenyl]ethyl}thieno[2,3-
Z?]pyridine-2-carboxamide, and 0 or salts, solvates or solvated salts thereof. A yet further embodiment of the invention relates to the compound selected from the group consisting of
3-amino-6-methyl-N-{2-[3-(methyloxy)phenyl]ethyl}-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide, 5 3-amino-6-methyl-N-[2-(2-thienyl)ethyl]-4-(trifluoromethyl)thieno[253-b]pyridine-2-car- boxamide,
3-amino-N-[2-(2,6-dichlorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-[2-(2-fluorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- io carboxamide,
3 -amino-6-methyl-N- [2-(phenyloxy)ethyl]-4-(trifluoromethyl)thieno [2,3 - b]py ridine-2-car- boxamide,
3-amino-N-(2,3-dihydro-l,4-benzodioxin-2-ylmethyl)-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide, is 3-amino-N-{2-[4-(ethyloxy)phenyl]ethyl}-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-6-methyl-N-(4-methylcyclohexyl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-amino-6-methyl-N-{2-[2-(phenyloxy)phenyl]ethyl}-4-(trifluoromethyl)thieno[2,3- 20. b]pyridine-2-carboxamide,
3-amino-6-methyl-N-{[5-methyl-2-(trifluoromethyl)-3-furanyl]methyl}-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide, l,l-dimethylethyl 4-({[3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridin-2- yljcarbonyl} amino)- 1 -piperidinecarboxylate, 25 3-amino-N-{[3-fluoro-5-(trifluoromethyl)phenyl]methyl}-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-6-methyl-4-(trifluoromethyl)-N-{[3-(trifluoromethyl)phenyl]methyl}thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-(3,3-dimethylbutyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-car- 30 boxamide,
3-amino-6-methyl-4-(trifluoromethyl)-N-({3-[(trifluoro- methyl)oxy]phenyl}methyl)thieno[2,3-b]pyridine-2-carboxamide, 3-ammo-N-{2-[4-(l,l-dimethylethyl)phenyl]ethyl}-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-6-methyl-N-{3-[methyl(phenyl)amino]propyl}-4-(trifluoromethyl)thieno[233- b]pyridine-2-carboxamide, 3-amino-N-[(3,5-dimetiiylphenyl)methyl]-6-metliyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-(cyclohexylmethyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-car- boxamide,
3-amino-N-butyl-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridme-2-carboxamide, 3-ammo-N-[2-(2,4-dichloropbeny])ethyi]-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide! ' .
3-amino-N-cyclohexyl-6~methyl-4-(trifluoroinethyl)thieno[2,3-b]pyridme-2-carboxamide,
3-amino-N-[(5-fluoro-2-methylphenyl)inethyϊ]-6-metb.yl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide, 3-ammo-N-[l-(4-fluorophenyl)ethyl]-6-metb.yl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-amino-6-methyl-N-(2-methylpropyl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carbox- amide,
3-amino-N-[(6-fluoro-4H-l,3-benzodioxin--8-yl)methyl]-6-methyl-4-(trifluoro- methyl)tbieno[2,3-b]pyridine-2-carboxamide,
3-amino-N,6-dimethyl-4-(trifluoroinethyl)-N-{[3-(trifluoro- methyl)phenyl]methyl}thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N-(2,3-dihydro-l-benzoforan-5-ylmethyl)-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide, 3-amino-6-methyl-N-[2-(2-pyridinyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridme-2- carboxamide, and
3-amino-6-methyl-N-[2-(4-pyridinyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide, or salts, solvates or solvated salts thereof.
Yet another embodiment of the invention relates to the compounds selected from the group consisting of 3-amino-6-methyl-N-[(2S)-2-phenylpropyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-amino-6-methyl-iV-[(2R)-2-phenylpropyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide, 3-amino-iV-[(2i?)-2-hydroxy-2-phenylethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-
Z>]pyridine-2-carboxamide,
3-amino-N-[(21S)-2-hydroxy-2-phenylethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-
Z?]pyridine-2-carboxamide,
3-amino-N-(2-hydroxy-2-phenylpropyl)-6-methyl-4-(trifluoromethyl)thieno[2,3- 6]pyridine-2-carboxamide,
3-amino-Ν-[2-(2-furyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carbox- amide,
3-amino-N-[2-(4-fluorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)tbieno[2,3-b]ι>yπdine-2- carboxamide, 3-amino-iV"-(2-cyclohexylethyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-ό]pyridine-2-car- boxamide,
3-amino-6-methyl-N-(trans-4-methylcyclohexyl)-4-(trifluoromethyl)thieno[2,3-ό]pyridme-
2-carboxamide,
6-methyl-3-(methylamino)-N-(2-phenylethyl)-4-(trifluoromethyl)thieno[253-b]pyridme-2- carboxamide,
3-(dimethylamino)-6-methyl-iV-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-Z?]pyridine-
2-carboxamide,
3-ammo-N-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N-[2-(4-methylphenyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carbox- amide, and
3-amino-N-[2-(3-fluorophenyl)ethyl]-4-(triiluoromethyl)thieno[2,3-b]pyridine-2-carbox- amide, or salts, solvates or solvated salts thereof.
For the avoidance of doubt it is to be understood that in this specification 'C1-6' means a carbon group having 1, 2, 3, 4, 5 or 6 carbon atoms. In this specification, unless stated otherwise, the term "alkyl" includes both straight and branched chain alkyl groups and may be, but are not limited to methyl, ethyl, n-propyl, i- propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl or i-hexyl, t-hexyl. The term C1-3 alkyl having 1 to 3 carbon atoms and may be methyl, ethyl, n-propyl, i-propyl or tert-butyl.
The term 'C0' means a bond or does not excist. For example when R1 is Coalkyl, R1 is a bond and "arylCoalkyl" is equivalent with "aryl", "C2alkylOC0alkyl" is equivalent with "C2alkylO".
In this specification, unless stated otherwise, the term "alkenyl" includes both straight and branched chain alkenyl groups. The term "C2-6alkenyl" having 2 to 6 carbon atoms and one or two double bonds, may be, but is not limited to vinyl, allyl, propenyl, butenyl, cro- tyl, pentenyl, or hexenyl, and a butenyl group may for example be buten-2-yl, buten-3-yl or buten-4-yl.
In this specification, unless stated otherwise, the term "alkynyl" includes both straight and branched chain alkynyl groups. The term "C2-6alkynyl" having 2 to 6 carbon atoms and one or two trippel bonds, may be, but is not limited to etynyl, propargyl, pentynyl or hexynyl and a butynyl group may for example be butyn-3-yl or butyn-4-yl.
In this specification, unless stated otherwise, the term "cycloalkyl" refers to an optionally substituted, saturated cyclic hydrocarbon ring system. The term "C3-7CyClOaUCyI" may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
In this specification, unless stated otherwise, the term "heterocycloalkyl" refers to a 3- to 7-membered, non-aromatic, partially or completely saturated hydrocarbon group, which contains one ring and at least one heteroatom. Examples of said heterocycle include, but are not limited to pyrrolidinyl, pyrrolidonyl, piperidinyl, piperazinyl, morpholinyl, oxa- zolyl, 2-oxazolidonyl or tetrahydrofuranyl. In this specification, unless stated otherwise, the term "aryl" refers to an optionally substituted monocyclic or bicyclic hydrocarbon unsaturated aromatic ring system. Examples of "aryl" may be, but are not limited to phenyl and naphthyl.
In this specification, unless stated otherwise, the term "heteroaryl" refers to an optionally substituted monocyclic or bicyclic unsaturated aromatic ring system containing at least one heteroatom selected independently form N, O or S. Examples of "heteroaryl" may be, but are not limited to pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thia- zolyl, pyrazolyl, benzofuryl, indolyl, isoindolyl, benzimidazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, tetrazolyl, triazolyl or oxazolyl.
In this specification, unless stated otherwise, the terms "arylalkyl" and "heteroarylalkyl" refer to a substiruent that is attached via the alkyl group to an aryl or heteroaryl group.
In this specification, unless stated otherwise, the term "4, 5, 6 or 7 membered ring" includes aryl, heteroaryl, cycloalkyl and heterocycloalkyl as defined above.
In this specification, unless stated otherwise, the terms "halo" and "halogen" may be fluoro, iodo, chloro or bromo.
In this specification, unless stated otherwise, the term "haloalkyl" means an alkyl group as defined above, which is substituted with halo as defined above. The term "d-δhaloalkyl" may include, but is not limited to fluoromethyl, difluoromethyl, trifluoromethyl, fluoro- ethyl, difluoroethyl or bromopropyl. The term "Ci-6haloalkylO" may include, but is not limited to fluoromethoxy, difluoromethoxy, trifluoromethoxy, fluoroethoxy or difluoroeth- oxy.
The present invention relates to the compounds of formula I as hereinbefore defined as well as to the salts, solvates or solvated salts thereof. Salts for use in pharmaceutical formulations will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I. A suitable pharmaceutically acceptable salt of the compounds of the invention is, for ex- ample, an acid-addition salt, for example a salt with an inorganic or organic acid. In addition, a suitable pharmaceutically acceptable salt of the compounds of the invention is an alkali metal salt, an alkaline earth metal salt or a salt with an organic base. Other pharmaceutically acceptable salts and methods of preparing these salts may be found in, for example, Remington's Pharmaceutical Sciences (18th Edition, Mack Publishing Co.).
Some compounds of formula I may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such op- tical, diastereoisomeric ar.d geometric isomers.
The invention also relates io any and all tautomeric forms of the compounds of formula I.
Medical use Surprisingly, it has been found that the compounds according to the present invention are useful in therapy. The compounds of formula I, or salts, solvates or solvated salts thereof, as well as their corresponding active metabolites, exhibit a high degree of potency and selectivity for individual vanilloid receptor 1 (VRl) groups. Accordingly, the compounds of the present invention are expected to be useful in the treatment of conditions associated with excitatory activation of vanilloid receptor 1 (VRl).
The compounds may be used to produce an inhibitory effect of VRl in mammals, including man.
VRl are highly expressed the peripheral nervous system and in other tissues. Thus, it is expected that the compounds of the invention are well suited for the treatment of VRl me- diated disorders.
The compounds of formula I are expected to be suitable for the treatment of acute and chronic pain, acute and chronic neuropathic pain and acute and chronic inflammatory pain. Examples of such disorder may be selected from the group comprising arthritis, rheuma- toid arthritis, spondylitis and gout, fibromyalgia, low back pain and sciatica, post-operative pain, cancer pain, migraine and tension headache, visceral pains like chronic pelvic pain, cystitis, including interstitial cystitis, pancreatitis, renal and biliary colic, menstruation as- sociated pain, pain related to ischeamic and angina, neuropathic pain disorders such as diabetic neuropathy, HIV neuropathy, chemotherapy induced neuropathies, post-herpetic neuralgia, post traumatic neuralgia and complex regional syndrome as well as itch.
Further relevant disorders may be selected from the group comprising gastroesophageal reflux disease (GERD), functional gastrointestinal disorders (FGD) such as irritable bowel syndrome (IBS), irritable bowel syndrome (IBS), and functional dyspepsia (FD).
Further examples of disorders are overactive bladder ("OAB"), a term for a syndrome that encompasses urge incontinence, urgency and frequency. Compounds of the invention may alleviate urinary incontinence ("UI") the involuntary loss of urine that results from an inability of the bladder to retain urine as a consequence of either urge (urge incontinence), or physical or mental stress (stress incontinence). Other relevant disorders may be psoriasis, and emesis.
Yet further relevant disorders are related to respiratory diseases and may be selected from the group comprising cough, asthma, chronic obstructive lung disease and emphysema, lung fibrosis and interstitial lung disease. • The VRl inhibitor(s) for respiratory use, may be administrated by either an oral or inhaled route. The respiratory disease may be an acute and chronic illness and may be related to infection(s) and/or exposure to environmental pollution and/or irritants. The compounds of formula I may also be used as antitoxin to treat (over-) exposure to VRl activators like capsaicin, tear gas, acids or heat. Regarding heat, there is a potential use for VRl antagonists in (sun-)burn induced pain, or inflammatory pain resulting from burn in- juries.
The compounds may further be used for treatment of tolerance to VRl activators.
One embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, in therapy.
Another embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of VRl mediated disorders. A further embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of acute and chronic pain.
Yet another embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of acute and chronic neuropathic pain.
Yet a further embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of acute and chronic inflammatory pain.
One embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of arthritis, rheumatoid arthritis, spondylitis and gout, fibromyalgia, low back pain and sciatica, post-operative pain, cancer pain, migraine and tension headache, visceral pains like chronic pelvic pain, cystitis, including interstitial cys- titis, pancreatitis, renal and biliary colic, menstruation associated pain, pain related to ischeamic and angina, neuropathic pain disorders such as diabetic neuropathy, HIV neuropathy, chemotherapy induced neuropathies, post-herpetic neuralgia, post traumatic neuralgia and complex regional syndrome as well as itch.
Another embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of gastroesophageal reflux disease, functional gastrointestinal disorders, irritable bowel syndrome, irritable bowel syndrome and functional dyspepsia.
A further embodiment of the invention relates to the use of the compounds of formula I as hereinbefore defined, for treatment of overactive bladder.
Yet a further embodiment of the invention relates to the use of the compound of formula I as hereinbefore defined, for the treatment of respiratory diseases selected from the group comprising of cough, asthma, chronic obstructive lung disease and emphysema, lung fibrosis and interstitial lung disease. One embodiment of the invention relates to the use of the compound of formula I as hereinbefore defined, in the manufacture of a medicament for treatment of VRl mediated disorders and for treatment of acute and chronic pain, acute and chronic neuropathic pain and acute and chronic inflammatory pain, and respiratory diseases, and any other disorder mentioned above.
Another embodiment of the invention relates to a method of treatment of VRl mediated disorders and acute and chronic pain, acute and chronic neuropathic pain and acute and chronic inflammatory pain, and respiratory diseases, and any other disorder mentioned above, comprising administrering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compounds -of formula I, as hereinbefore defined.
A further embodiment of the invention relates to a pharmaceutical composition comprising a compound of formula I as hereinbefore defined, for use in treatment of VRl mediated disorders and for treatment of acute and chronic pain, acute and chronic neuropathic pain and acute and chronic inflammatory pain, and respiratory diseases, and any other disorder mentioned above.
In the context of the present specification, the term "therapy" and "treatment" includes prevention and prophylaxis, unless there are specific indications to the contrary. The terms "treat'7'therapeutic" and "therapeutically" should be construed accordingly.
In this specification, unless stated otherwise, the term "inhibitor" and "antagonist" mean a compound that by any means, partly or completely, blocks the transduction pathway lead- ing to the production of a response by the ligand.
The term "disorder", unless stated otherwise, means any condition and disease associated with vanilloid receptor activity.
Non- Medical use
In addition to their use in therapeutic medicine, the compounds of the invention, or salts, solvates or solvated salts thereof, are also useful as pharmacological tools in the develop- ment and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of VRl related activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutics agents.
5 Pharmaceutical composition
According to one embodiment of the present invention there is provided a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound of formula I, or salts, solvates or solvated salts thereof, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers. 0
, The composition may be in a form suitable for oral administration, for example as a- tablet, pill, syrup, powder, granule or capsule, for parenteral injection (including intravenous, . subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration e.g. as an ointment, patch or cream or for rectal ad- 5 ministration e.g. as a suppository.
In general the above compositions may be prepared in a conventional manner using one or more conventional excipients, pharmaceutical acceptable diluents and/or inert carriers. Suitable daily doses of the compounds of formula I in the treatment of a mammal, including man, are approximately 0.01 to 250 mg/kg bodyweight at peroral administration and o about 0.001 to 250 mg/kg bodyweight at parenteral administration.
The typical daily dose of the active ingredient varies within a wide range and will depend on various factors such as the relevant indication, severity of the illness being treated, the route of administration, the age, weight and sex of the patient and the particular compound being used, and may be determined by a physician. 5
Examples of pharmaceutical composition
The following illustrate representative pharmaceutical dosage forms containing a compound of formula I, or salts, solvates or solvated salts thereof, (hereafter compound X) for 0 preventive or therapeutic use in mammals:
Figure imgf000021_0001
Figure imgf000021_0002
Figure imgf000021_0003
The above compositions may be obtained by conventional procedures well known in the pharmaceutical art.
Methods of Preparation
Throughout the following description of such processes it is to be understood that, where appropriate, suitable protecting groups will be added to, and subsequently removed from, the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis. Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are described, for example, in "Protective Groups in Organic Synthesis", T.W. Green, P.G.M. Wuts, Wiley-Interscience, New York, (1999). References and descriptions of other suitable reactions are described in textbooks of organic chemistry, for example, "Advanced Organic Chemistry", March, 4th ed. McGraw Hill (1992) or, "Organic Synthesis", Smith, McGraw Hill, (1994). For representative examples of heterocyclic chemistry see for example "Heterocyclic Chemistry", J. A. Joule, K. Mills, G. F. Smith, 3rd ed. Chapman and Hall (1995), p. 189-224 and "Heterocyclic Chemistry", T. L. Gilchrist, 2nd ed. Longman Scientific and Technical (1992), p. 248-282.
The term "room temperature" and "ambient temperature" shall mean, unless otherwise specified, a temperature between 16 and 25 °C.
One embodiment of the invention relates to processes for the preparation of the compound of formula I according to scheme 1, 2, 3, 4, 5, or 6; wherein R1 to R9, X, n and p are as de~ fined above;
Scheme 1
Figure imgf000022_0001
Intermediate 1
Figure imgf000022_0002
Intermediate 3
Scheme 2
Figure imgf000022_0003
Scheme 3
Figure imgf000022_0004
Scheme 4
Figure imgf000023_0001
Scheme 5
Figure imgf000023_0002
Figure imgf000023_0003
Intermediate 6
Intermediate 5
Figure imgf000023_0004
Intermediate 7
Intermediates
One embodiment of the invention relates to the compounds 4-(trifluoromethyl)nicotinonitrile 1 -oxide, i o 2-chloro-4-(trifluoromethyl)nicotinonitrile,
3-amino-4-(trifluoromethyl)thieno[2,3-έ]pyridine-2-carboxylic acid, and 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxylic acid, which may be used as intermediates in the preparation of compounds suited for the treatment of VRl mediated disorders, especially for use as intermediates for the preparation of is compounds of formula I. Examples
The invention will now be illustrated by the following non-limiting examples.
General methods
The invention will now be illustrated by the following Examples in which, generally :
(i) operations were carried out at ambient or room temperature, i.e. in the range 17 to 25°C and under an atmosphere of an inert gas such as argon unless otherwise stated; (ii) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids by filtration;
(iii) column chromatography (by the flash procedure) was performed on Silicycϊe silica gel (grade 230-400 mesh, 60 A, cat. Numb. Rl 0030B) or obtained from Silicycle, Quebec, Canada or high pressure liquid chromatography (HPLC) was performed on Cl 8 re- verse phase silica, for example on a Phenomenex, Luna C- 18 IOOA preparative reversed- phase column;
(iv) The 1H NMR spectra were recorded on Brucker at 400 MHz. The mass spectra were recorded utilising electrospray (LC-MS; LC:Waters 2790, column XTerra MS C8 2.5 μm 2.1X30 mm, buffer gradient H2O+0.1%TFA:CH3CN+0.04%TFA, MS: micromass ZMD// ammonium acetate buffer) ionisation techniques;
(v) yields, where present, are not necessarily the maximum attainable; (vi) intermediates were not necessarily fully purified but their structures and purity were assessed by thin layer chromatographic, HPLC and/or NMR analysis
(vii)the following abbreviations have been used:- HATU O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
HPLC high performance liquid chromatography LC liquid chromatography
MS mass spectometry ret. time retention time TFA trifluroacetic acid
DMF dimethyformamide DIPEA Diisopropylethylamine NEt3 Triethylamine
General Procedure 1 for Amide Formation Between a Carboxylic Acid and Amine:
Figure imgf000025_0001
The amine (1 equiv.) was added to a solution of the 3-aminothieno[2,3-Z>]pyridine-2-car-
' boxylic acid (1 equiv.), HATU (1.1 equiv.) and DIPEA (1.5 equiv.) in DMF (10 mL/mmol of carboxylic acid). The reaction was stirred overnight at room temperature and was then concentrated in vacuo. The residue was redissolved in CH2Cl2 and saturated NaHCO3(aq), and the resulting mixture was loaded onto an Extube® Chem Elut column (Varian). The compound was eluted with four column, volumes of CH2Cl2. The eluant was concentrated in vacuo, and the crude product was purified by silica gel column chromatography or reverse phase HPLC to provide the title compound.
General Procedure 2 for Amide Formation Between a Carboxylic Acid and Amine in Plate Format:
(R5)
Figure imgf000025_0002
Stock solutions of the 3-aminothieno[2,3-Z>]pyridine-2-carboxylic acids (0.625 M), amines (0.25 M), HATU (0.55 M), and DIPEA (0.75 M) in DMF were prepared. The solutions of the carboxylic acids were dispensed into 96-well plates (200 μL/well), followed by HATU (250 μL/well), DIPEA (250 μL/well) and the amines (500 μL/well). The 96-well plates were agitated for 2 days, and were then concentrated in vacuo. The residues were redissolved in CH2Cl2 and 5 % NaOH(aq), mixed, and then filtered through a Unifilter® plate containing Hydromatrix.® The wells were rinsed with additional CH2Cl2, and the combined filtrates were concentrated in vacuo. The products were purified by reverse phase HPLC to provide the title compounds. Compounds prepared by this route are listed in Table 1.
Examples
Intermediate 1: 6-methyl-2-thioxo-4-(trifluoromethyl)-l,2-dihydropyridine-3-carbonitrile
Figure imgf000026_0001
A mixture of l,l,l-trifluoropentane-2,4-dione (8.159 g, 52.9 mmol), 2-cyano- ethanethioamide (5.302 g, 52.9 mmol) and triethylamine (0.27 ml,, 1.9 mmol) v/as heated ' in refluxing ethanol (42 mL) for 20 minutes. The reaction was allowed to cool, -and. the resulting orange solid was transferred to a round bottomed flask using methanol and
CH2Cl2. The mixture was concentrated in vacuo to provide the title compound, which was used in subsequent steps without further purification. 1H NMR (400 MHz3 DMSO-D6): δ ppm 2.46 (s, 3 H)3 7.13 (s, 1 H).
Intermediate 2: ethyl 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-^]pyridine-2-car- boxylate
Figure imgf000026_0002
To a mixture of 6-methyl-2-thioxo-4-(trifluoromethyl)-l,2-dihydropyridine-3-carbonitrile (11.5 g3 52.9 mmol) and ethyl bromoacetate (5.9 mL, 53 mmol) in ethanol (235 mL) was added sodium ethoxide (5.40 g3 79 mmol). The reaction was heated to reflux for 2 hours, and additional sodium ethoxide was added, if necessary, until the cyclization was complete as determined by 1H-NMR. The reaction was concentrated in vacuo, and the residue was taken up in water and CH2Cl2. The layers were separated, and the aqueous layer was extracted with additional CH2Cl2 (3x). The combined organic phases were dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by silica gel chromatography eluting with CH2Cl2 to provide the title compound as a yellow solid (14.6 g, 91%). 1HNMR (400 MHz, CDCl3) δ ppm 1.39 (t, J=IA Hz, 3 H), 2.73 (s, 3 H), 4.36 (q, J=7.0 Hz, 2 H), 6.34 (br s, 2 H), 7.41 (s, 1 H)
Intermediate s: 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-&]pyridine-2-carboxylic 5 acid
Figure imgf000027_0001
A mixture of ethyl 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-&]pyridine-2-carboxy- late (14.6 g, 48.0 mmol) and potassium hydroxide (6.73 g, 120 mmol) in 5.5:1 metha- nol:water (260 mL) was heated at reflux for 4.5 hours. The reaction was concentrated in o vacuo, and the residue was taken up in water (90 mL). The pH of the water solution was adjusted to 2 using IM HCl, and the precipitated yellow solid was collected by filtration. The solid was suspended in water and lyophilized to provide the title compound as a yellow solid (12.5 g, 94%). 1H NMR (400 MHz, CD3OD) δ ppm 2.71 (s, 3 H), 7.64 (s, 1 H)
s Compound 1: 3-amino-6-methyl-iV-(3-phenylpropyl)-4-(trifluoromethyl)thieno[2,3- δ]pyridine-2-carboxamide
Following General. Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3- έ]pyridine-2-carboxylic acid (0.0769 g, 0.28 mmol), HATU (0.116 g, 0.31 mmol), DIPEA (0.073 mL, 0.42 mmol) and (3-phenylpropyl)amine (0.040 mL, 0.28 mmol) were com- 0 bined. The title compound was obtained as a yellow gum (0.0839 g, 77%) following purification by reverse phase HPLC (gradient 30-90% CH3CN in H2O) and lyophilization from CH3CN/H2O. Purity (HPLC): >99%; 1H-NMR (400 MHz, CDCl3): δ ppm 1.92 - 2.02 (m, 2 H), 2.68 - 2.76 (m, 5 H), 3.39 - 3.51 (m, 2 H), 5.54 (t, J=5.5 Hz, 1 H)3 6.48 (br s, 2 H), 7.15 - 7.23 (m, 3 H), 7.26 - 7.33 (m, 2 H), 7.44 (s, 1 H). MS (ESI) (M+H)+ = 394. Anal. s Calcd for Ci9H18N3OSF3 + 0.2 H2O: C, 57.48; H, 4.67; N, 10.58. Found: C, 57.51; H, 4.40; N, 10.54.
Compound 2: 3-amino-6-methyl-iV-[2-(4-niethylphenyl)ethyl]-4-(trifluoro- methyl)thieno[2,3-δ]pyridine-2-carboxamide Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3- Z>]pyridine-2-carboxylic acid (0.0751 g, 0.27 mmol), HATU (0.114 g, 0.30 mmol), DIPEA (0.070 mL, 0.40 mmol) and [2-(4-methylρhenyl)ethyl] amine (0.54 mL of a 0.5 M DMF solution, 0.27 mmol) were combined. The title compound was obtained as a yellow solid 5 (0.0472 g, 44%) following purification by reverse phase HPLC (gradient 60-100% CH3CN in H2O) and lyophilization from CH3CN/H2O. Purity (HPLC): >98%; 1H-NMR (400 MHz, CDCl3): δ ppm 2.33 (s, 3 H), 2.72 (s, 3 H), 2.87 (t, J=6.9 Hz, 2 H), 3.60 - 3.69 (m, 2 H), 5.53 - 5.66 (m, 1 H), 6.48 (br s, 2 H), 7.09 - 7.17 (m, 4 H), 7.44 (s, 1 H). MS (ESI) (M+H)+ = 394. Anal. Calcd for C19H18N3OSF3 + 0.1 TFA: C, 56.96; H, 4.51; N, 10.38. io Found: C, 57.03; H, 4.50; N, 10.26. . ,
Compound 3: 3-amino-6-methyl-N-[2-(2-methylphenyl)ethyl]-4-(trifluoro- methyl)thieno[2,3-6]pyridine-2-carboxamide
Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieno|2,3-
I5 έ]pyridine-2-carboxylic acid (0.0751 g, 0.27 mmol), HATU (0.114 g, 0.30 mmol), DIPEA (0.070 mL, 0.40 mmol) and [2-(2-methylphenyl)ethyl]amine (0.54 mL of a 0.5 M DMF solution, 0.27 mmol) were combined. The title compound was obtained as a yellow solid (0.0820 g, 77%) following purification by reverse phase HPLC (gradient 60-100% CH3CN in H2O) and lyophilization from CH3CN/H2O. Purity (HPLC): >98%; 1H-NMR (400
20 MHz, CDCl3): δ ppm 2.37 (s, 3 H), 2.73 (s, 3 H), 2.93 (t, J=7.1 Hz, 2 H), 3.57 - 3.71 (m, 2 H), 5.62 (t, J=5.4 Hz, 1 H), 6.50 (br s, 2 H), 7.13 - 7.22 (m, 4 H), 7.44 (s, 1 H). MS (ESI) (M+H)+ = 394. Anal. Calcd for C19Hi8N3OSF3: C, 58.01; H, 4.61; N, 10.68. Found: C, 57.79; H, 4.35; N, 10.41.
5 Compound 4: 3-amino-6-methyl-iV-(2-phenylpropyl)-4-(trifluoromethyl)thieno[2,3- έ]pyridine-2-carboxamide
Following General Procedure 1, 3-amino-6-methyl-4-(trifluorofnethyl)thieno[2,3- Z?]pyridine-2-carboxylic acid (0.0751 g, 0.27 mmol), HATU (0.114 g, 0.30 mmol), DIPEA (0.070 mL, 0.40 mmol) and (2-phenylpropyl)amine (0.54 mL of a 0.5 M DMF solution, 0 0.27 mmol) were combined. The title compound was obtained as a yellow solid (0.0755 g, 71%) following purification by reverse phase HPLC (gradient 50-80% CH3CN in H2O) and lyophilization from CH3CNfR2O. Purity (HPLC): >96%; 1H-NMR (400 MHz, CDCl3): δ ppm 1.35 (d, J=6.8 Hz, 3 H), 1.83 (tar s, 2 H)3 2.71 (s, 3 H), 2.97 - 3.12 (m, 1 H), 3.35 (ddd, J=U 3, 8.5, 4.9 Hz, 1 H), 3.78 (ddd, J=13.3, 7.0, 6.1 Hz, 1 H), 5.43 (t, J=5.4 Hz, 1 H), 7.18 - 7.29 (m, 3 H), 7.31 - 7.39 (m, 2 H), 7.43 (s, 1 H). MS (ESI) (M+H)+ = 394. Anal. Calcd for C19H18N3OSF3 + 0.1 TFA + 0.2 H2O: C, 56.46; H, 4.57; N, 10.29. s Found: C, 56.35; H, 4.45; N, 10.36.
Compound 5: 3-aniino-iV,6-dimethyl-iV-(2-phenylethyl)-4-(trifluorornethyl)tliieno[2,3-
6]pyridine-2-carboxamide
Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3- o £]pyridine-2-carboxylic acid (0.0751 g, 0.27 mmol), HATU (0.114 g, 0.30 mmol), DIPEA (0.070 mL, 0.40 mmol) and N-methyl-2-phenylethanamine (0.54 mL of a 0.5 M DMF solution, 0.27 mmol) were combined. The title compound was obtained as a yellow solid (0.0748 g, 70%) following purification by reverse phase HPLC (gradient 50-80% CH3CN in H2O) and lyophilization from CH3CN/H2O. Purity (HPLC): >95%; 1H-NMR (400 s MHz, CDCl3): δ ppm 2.73 (s, 3 H), 2.95 - 3.03 (m, 2 H), 3.14 (s, 3 H), 3.76 - 3.86 (m, 2 H), 7.17 - 7.33 (m, 5 H), 7.44 (s, I H). MS (ESI) (M+H)+ = 394. Anal. Calcd for C19H18N3OSF3 + 0.1 TFA: C, 56.96; H, 4.51; N, 10.38. Found: C, 56.99; H, 4.40; N, 10.78. '
0 Compound 6: 3-amino-iV-[2-(2-methoxyphenyl)ethyl]-6-methyl-4-(trifluoro- methyl)thieno[2,3-έ]pyridine-2-carboxamide
Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3- %yridine-2-carboxylic acid (0.0751 g, 0.27 mmol), HATU (0.114 g, 0.30 mmol), DIPEA (0.070 mL, 0.40 mmol) and [2-(2-methoxyphenyl)ethyl] amine (0.54 mL of a 0.5 M DMF 5 solution, 0.27 mmol) were combined. The title compound was obtained as a yellow solid (0.0782 g, 70%) following purification by reverse phase HPLC (gradient 50-80% CH3CN in H2O) and lyophilization from CH3CN/H2O. Purity (HPLC): >98%; 1H-NMR (400 MHz, CDCl3): δ ppm 2.04 (br s, 1 H), 2.73 (s, 3 H), 2.92 - 2.98 (m, 2 H), 3.61 - 3.67 (m, 2 H), 3.94 (s, 3 H), 6.17 (t, 7=4.1 Hz, 1 H), 6.48 (br s, 1 H), 6.87 - 6.92 (m, 1 H), 6.92 - 6.96 (m, 1 H), 7.18 (dd, J=IA, 1.8 Hz, 1 H), 7.22 (dd, J=I.5, 1.7 Hz, 1 H), 7.43 (s, 1 H). MS (ESI) (M+H)+ = 410. Anal. Calcd for C19Hi8N3O2SF3 + 0.2 H2O: C, 55.25; H, 4.49; N, 10.17. Found: C, 55.11; H, 4.30; N, 10.26. Compound 7: 3-amino-iV'-(2,2-diphenylethyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-
&]pyridine-2-carboxamide
Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3- 6]ρyridine-2-carboxylic acid (0.0751 g, 0.27 mmol), HATU (0.114 g, 0.30 mmol), DIPEA (0.070 mL, 0.40 mmol) and (2,2-diphenylethyl)amine (0.54 mL of a 0.5 M DMF solution, 0.27 mmol) were combined. The title compound was obtained as a yellow solid (0.0849 g, 69%) following purification by reverse phase HPLC (gradient 60-100% CH3CN in H2O) and lyophilization from CH3CNZH2O. Purity (HPLC): >98%; 1H-NMR (400 MHz, CDCl3): δ ppm 1.60 (br s, 1 H), 2.70 (s, 3 H), 4.05 (dd, J=I.9, 5.8 Hz, 2 H), 4.27 (t, J=7.9 Hz, 1 H), 5.48 (t, J=5.5 Hz, 1 H), 6.46 (br s, 1 H), 7.20 - 7.37 (m, 10 H), 7.42 (s, 1 H). MS (ESI) (M+H)+ = 456. Anal. Calcd for C24H20N3OSF3 + 0.1 TFA: Q.62.25; H, 4.34; N, 9.00. Found: C, 62.44; H, 4.21; N, 8.87.
Compound 8: 3-amino-iV-[2-(3-fluorophenyl)ethyl]-6-methyl-4-(trifiuoro- methyl)thieno[2,3-έ]pyridine-2-carboxamide
Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieHθ[2,3- 6]pyridine-2-carboxylic acid (0.0751 g, 0.27 mmol), HATU (0.114 g, 0.30 mmol), DIPEA (0.070 mL, 0.40 mmol) and [2-(3-fluorophenyl)ethyl]amine (0.54 mL of a 0.5 M DMF solution, 0.27 mmol) were combined. The title compound was obtained as a yellow solid (0.0752 g, 70%) following purification by reverse phase HPLC (gradient 50-80% CH3CN in H2O) and lyophilization from CH3CN/H2O. Purity (HPLC): >98%; 1H-NMR (400 MHz, CDCl3): δ ppm 1.59 (br s, 1 H), 2.73 (s, 3 H), 2.92 (t, J=7.0 Hz, 2 H), 3.67 (q, 2 H), 5.59 (t, J=5.6 Hz, 1 H), 6.50 (br s, 1 H), 6.89 - 6.98 (m, 2 H), 7.01 (d, J=8.0 Hz, 1 H), 7.25 - 7.33 (m, 1 H), 7.44 (s, 1 H). MS (ESI) (M+H)+ = 398. Anal. Calcd for C18H15N3OSF4: C, 54.40; H, 3.80; N, 10.57. Found: C, 54.10; H, 3.64; N, 10.59.
Compound 9: 3-amino-iV-[2-(3,4-dichlorophenyl)ethyl]-6-methyl-4-(trifluoro- methyl)thieno[2,3-δ]pyridine-2-carboxamide Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-
Z>]pyridine-2-carboxylic acid (0.0751 g, 0.27 mmol), HATU (0.114 g, 0.30 mmol), DIPEA (0.070 mL, 0.40 mmol) and [2-(3,4-dichlorophenyl)ethyl]amine (0.54 mL of a 0.5 M DMF solution, 0.27 mmol) were combined. The title compound was obtained as a yellow solid (0.0791 g, 65%) following purification by reverse phase HPLC (gradient 60-100% CH3CN in H2O) and lyophilization from CH3CN/H2O. Purity (HPLC): >98%; 1H-NMR (400 MHz, CDCl3): δ ppm 1.58 (br s, 1 H), 2.73 (s, 3 H), 2.88 (t, J=7.0 Hz, 2 H), 3.64 (q, J=6.1 Hz, 2 H), 5.60 (t, J=5.8 Hz, 1 H), 6.51 (br s, 1 H), 7.07 (dd, J=8.1, 2.1 Hz, 1 H), 7.34 (d, J=2.1 Hz, 1 H), 7.38 (d, J=8.2 Hz, 1 H), 7.45 (s, 1 H). MS (ESI) (M+H)+ = 448. Anal. Calcd for C18H14N3OSF3Cl2: C, 48.23; H, 3.15; N, 9.37. Found: C, 47.99; H, 2.98; N, 9.30.
Compound 10: 3-amino-6-methyl-4-(trifluoromethyl)-iV-{2-[3-(trifluoro- methyl)phenyi]ethyl}mieno[2,3-έ]pyridine-2-carboxamide Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3- 6]pyridine-2-carboxyiic acid (0.0751 g, 0.27 mmol), HATU (0.114 g, 0.30 mmol), DIPEA (0.070 mL, 0.40 mmol) and {2-[3-(trifluoromethyl)phenyl]ethyl} amine (0.54 mL of a 0.5 M DMF solution, 0.27 mmol) were combined. The title compound was obtained as a yellow solid (0.0814 g, 67%) following purification by reverse phase HPLC (gradient 60- 100% CH3CN in H2O) and lyophilization from CH3CN/H2O. Purity (HPLC): >96%; 1H- NMR (400 MHz, CDCl3): δ ppm 1.57 (br s, 1 H), 2.73 (s, 3 H), 2.99 (t, J=7.1 Hz, 2 H), 3.63 - 3.73 (m, 2 H), 5.61 (t, J=5.8 Hz, 1 H), 6.51 (br s, 1 H), 7.40 - 7.47 (m, 3 H), 7.48 - 7.54 (m, 2 H). MS (ESI) (M+H)+ - 448. Anal. Calcd for C19H15N3OSF6 + 0.1 TFA: C, 50.26; H, 3.32; N, 9.16. Found: C, 50.17; H, 3.17; N, 9.18.
Intermediate 4: 2-chloro-N-(2-phenylethyl)acetamide
Figure imgf000031_0001
Chloroacetyl chloride (1.95 mL, 24.5 mmol) was added dropwise to a mixture of (2- phenylethyl)amine (2.476 g, 20.4 mmol) and sodium bicarbonate (2.16 g, 25.7 mmol) in CH2Cl2 (20 mL) maintained at 0 0C. The reaction was stirred for 2.5 hours at 10 0C, and was then cooled back down to 0 0C and quenched by the addition of water (10 mL). The layers were separated, and the organic phase was washed successively with 10% HCl(aq) and brine. The organic phase was then dried over Na2SO4, filtered, and concentrated in vacuo to provide the title compound (4.13 g, quantitative), which was used in subsequent steps without further purification. 1H NMR (400 MHz, CDCl3): δ ppm 2.86 (t, J=7.0 Hz, 2 H), 3.51 - 3.64 (m, 2 H), 4.04 (s, 2 H), 6.63 (br s, 1 H), 7.18 - 7.28 (m, 3 H), 7.30 - 7.37 (m, 2 H).
Compound 11 : 3-amino-6-methyl-iV-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3- έ]pyridine-2-carboxamide
To a solution of 6-methyl-2-thioxo-4-(trifluoromethyl)-l,2-dihydropyridine-3-carbonitrile (0.259 g, 1.19 mmol) in DMF (2 mL) was added 2-chloro-iV-(2-phenylethyl)acetamide (0.234 g, 1.19 mmol) in portions and a solution of 15% sodium hydroxide in water (0.65 mL, 1.8 mmol) dropwise. The resulting mixture was stirred at room temperature for 3.5 hours, and was then diluted with water (10 mL) and CH2Cl2 (20 mL). The layers were separated, and the aqueous layer was extracted with additional CH2Cl2 (3x). The com- bined organic phases were washed with brine (2x), and then dried .over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by silica gel chromatography eluting with 5:1 CH2Cl2 :EtO Ac, followed by a second purification eluting with 3:1 hex- anes:EtOAc, to provide the title compound as a yellow solid (0.211 g, 47%). Purity (HPLC): >99%; 1H-NMR (400 MHz, CDCl3): δ ppm 2.73 (s, 3 H), 2.93 (t, j=6.9 Hz, 2 H), 3.65-3.72 (m, 2 H), 5.61 (t, J=5.7 Hz, 1 H), 6.51 (br s, 2 H), 7.22 - 7.30 (m, 3 H), 7.30 - 7.38 (m, 2 H), 7.45 (s, 1 H). MS (ESI) (M+H)+ = 380. Anal. Calcd for C18Hi6N3OSF3: C, 56.98; H, 4.25; N, 11.08. Found: C, 56.64; H, 4.21; N, 10.93.
Compound 12 : 3-amino-6-methyl-N-[(2S)-2-phenylpropyl]-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide
Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3- Z?]pyridine-2-carboxylic acid (0.200 g, 0.72 mmol), HATU (0.303 g, 0.78 mmol), DIPEA (0.19 mL, 1.08 mmol), and (S)-(-)-β-methylphenethylamine (155 μL, 1.08 mmol) were combined. The title compound was obtained as a yellow solid (0.248 g, 87%) following purification by reverse phase HPLC (gradient 30-90% CH3CN in H2O) and lyophilization from CH3CN/H2O. Purity (HPLC): >99%; Chiral Purity (HPLC): >99%; 1H NMR (400 s MHZ, CDCl3): δ ppm 1.36 (d, J=7.03 Hz, 3 H), 2.72 (s, 3 H), 3.00 - 3.18 (m, 1 H), 3.32 - 3.41 (m, 1 H), 3.75 - 3.84 (m, 1 H), 5.43 (t, J=5.66 Hz, 1 H), 6.47 (s, 2 H), 7.24 - 7.29 (m, 3 H), 7.33 - 7.39 (m, 2 H), 7.44 (s, 1 H). MS (ESI) (M+H)+ = 394. Anal. Calcd for C19H18F3N3OS + 0.15 H2O: C, 57.61; H, 4.66; N, 10.61. Found: C5 57.48; H, 4.48; N5 10.45. Optical Rotation: [α]D 18 = -76.9 ° (c = 0.963, MeOH). 0
Compound 13: 3-amino-6-methyl-iV-[(2R)-2-phenylpropyl]-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide
Following General Procedure I5 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-
%yridine-2-carboxylic acid (0.150 g, 0.54 mmol), HATU (0.310 g, 0.81 mmol), DIPEA s (0.24 mL, 1.38 mmol), and (R)-(+)-β-methylphenethylamine (110 μL, 0.77 mmol) were combined. The title compound was obtained as a yellow solid (0.143 g, 67%) following purification by column chromatography (25% ethyl acetate in hexanes). Purity (HPLC): >99%; Chiral Purity (HPLC): >99%; 1H NMR (400 MHZ, CD3OD): δ ppm 1.28 (d, J=7.0 . Hz, 3 H), 2.99 (s, 3 H), 3.03 -3.14 (m, 1 H), 3.45 - 3.51 (m, 2 H), 7.13 - 7.19 (m, 1 H), 7.22 0 - 7.30 (m, 4 H); 7.64 (s, 1 H). MS (ESI) (M+H)+ = 394. Anal. Calcd for C19H18F3N3OS x ■ 0.2HC1: C5 56.95; H, 4.58; N5 10.49. Found: C, 57.06; H, 4.47; N, 10.67.
Compound 14: 3-amino-iV-[(2i?)-2-hydroxy-2-phenylethyl]-6-methyl-4-(trifluoro- methyl)thieno[2,3-Z>]pyridine-2-carboxamide 5 Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-
6]pyridine-2-carboxylic acid (0.0751 g, 0.27 mmol), HATU (0.114 g, 0.30 mmol), DIPEA (0.14 mL, 0.80 mmol), and (li?)-2-amino-l-phenylethanol (0.0370 g, 0.27 mmol) were combined. The title compound was obtained as a yellow solid (0.0638 g, 59%) following purification by reverse phase HPLC (gradient 50-80% CH3CN in H2O) and lyophilization o from CH3CN/H2O. Purity (HPLC): >99%; 1H NMR (400 MHZ, CDCl3): δ ppm 2.73 (s, 3 H), 3.28 (d, J=3.5 Hz, 1 H), 3.52 (ddd, J=14.1, 8.0, 5.1 Hz, 1 H), 3.85 (ddd, 7=14.2, 6.9, 3.3 Hz, 1 H), 4.96 (ddd, J=I.6, 3.7, 3.4 Hz, 1 H), 5.99 (t, J=5.7 Hz, 1 H), 6.53 (s, 2 H),
7.27 - 7.34 (m, 1 H)3 7.34 - 7.44 (m, 4 H), 7.45 (s, 1 H). MS (ESI) (M+H)+ = 396.
Compound 15: 3-atnmo-iV:-[(2iS)-2-hydroxy-2-phenylethyl]-6-methyl-4-(trifluoro- s methyl)thieno[2,3-6]pyridine-2-carboxamide
Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)mieno[2,3- Z>]pyridine-2-carboxylic acid (0.0751 g, 0.27 mmol), HATU (0.114 g, 0.30 mmol), DIPEA . (0.14 mL, 0.80 mmol), and (lS>2-amino-l-phenylethanol (0.0370 g, 0.27 mmol) were combined. The title compound was obtained as a yellow solid (0.0631 g, 59%) following o purification by reverse phase HPLC (gradient 50-80% CH3CN in H2O) and lyophilization from CH3CNZH2O. Purity (HPLC): >99%: 1H NMR (400 MHZ, CDCl3): δ ppm 2.73 (s, 3 H), 3.27 (d, J=3.3 Hz, 1 H), 3.53 (ddd, J-14.1, 8.0, 5.1 Hz, 1 H), 3.85 (ddd, J=14.2, 6.8, 3.2 Hz, 1 H), 4.96 (ddd, J=7.6, 3.7, 3.4 Hz, I H), 5.98 (t, J=β.l Hz, 1 H), 6.53 (s, 2 H),
7.28 - 7.33 (m, 1 H), 7.34 - 7.44 (m, 4 H), 7.45 (s, 1 H). MS (ESI) (M+H)+ = 396. Anal. s Calcd for C18H16F3N3O2 S + 0.1 H2O: C, 54.43; H, 4.11; N3 10.58. Found: C, 54.43; H,
3.81; N, 10.29.
Compound 16: 3-amino-iV-(2-hydroxy-2-phenylpropyl)-6-methyl-4-(triiluoro- methy l)thieno [2,3 -&]pyridine-2-carboxamide 0 Following a modified version of General Procedure 1 employing additional DIPEA, 3- amino-6-methyl-4-(trifluoromethyl)thieno[2,3-έ]pyridine-2-carboxylic acid (0.101 g, 0.37 mmol), HATU (0.153 g, 0.40 mmol), DIPEA (0.19 mL, 1.1 mmol), and l-amino-2- phenylpropan-2-ol hydrochloride (0.0685 g, 0.37 mmol) were combined. The title compound was obtained as a yellow solid (0.125 g, 84%) following purification by column 5 chromatography (3:1 CH2Cl2 :EtOAc). Purity (HPLC): >99%; 1H NMR (400 MHZ, CDCl- 3): δ ppm 1.62 (s, 3 H), 2.70 (s, 3 H), 3.44 (s, 1 H), 3.55 (dd, J=14.0, 5.2 Hz, 1 H), 3.88 (dd, J=14.1, 7.0 Hz, 1 H), 5.84 (t, J=5.8 Hz, 1 H), 6.48 (s, 2 H), 7.23 - 7.30 (m, 1 H), 7.32 - 7.39 (m, 2 H), 7.42 (s, 1 H), 7.46 - 7.54 (m, 2 H). MS (ESI) (M+H)+ = 410. Anal. Calcd for C19H18F3N3O2 S + 0.2 H2O: C, 55.25; H, 4.49; N, 10.17. Found: C, 55.24; H, 4.38; N, o 10.50. Compound 17: 3-amino-N-[2-(2-flιryl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide
Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-
£]pyridine-2-carboxylic acid (0.150 g, 0.54 mmol), HATU (0.227 g, 0.60 mmol), DIPEA
5 (0.14 mL, 0.81 mmol), and 2-furan-2-yl-ethylamine (167 mg, 0.81 mmol) were combined. The title compound was obtained as a yellow solid (0.090 g, 45%) following purification by reverse phase HPLC (gradient 30-90% CH3CN in H2O) and lyophilization from CH- 3CN/H2O. Purity (HPLC): >99%; 1H NMR (400 MHZ, CDCl3): δ ppm 2.74 (s, 3 H) 2.96 (t, J=6.54 Hz5 2 H) 3.70 (q, J=6.58 Hz, 2 H) 5.80 (t, J=5.37 Hz, 1 H) 6.13 (dd, J=3.32, 0.78 jo Hz, 1 H) 6.32 (dd, J=3.12, 1.76 Hz, 1 H) 6.50 (s, 2 H) 7.37 (dd, J=1.86, 0.88 Hz3 1 H) 7.45 (s, 1 H). MS (ESI) (M+H)+ = 370. Anal. Calcd for C16H14F3N3O2S: C, 52.03; H5 3.82; N5 .11.38. Found: C5 51.80; H, 3.64; N5 11.63.
Compound 18: 3-amino-N-[2-(4-fluorophenyl)ethyl]-6-methyl-4-(trifluoro-
I5 memyl)thieno[2,3-b]pyridine-2-carboxamide
Following General Procedure 1, 3-amino-6-methyl-4-(trifluoromethyl)thieno[253- 6]pyridine-2-carboxylic acid (0.150 g, 0.54 mmol), HATU (0.227 g, 0.60 mmol), DIPEA (0.14 mL, 0.81 mmol), and 4-fluorophenethylamine (106 μL, 0.81 mmol) were combined. The title compound was obtained as a yellow solid (0.100 g, 45%) following purification 0 by reverse phase HPLC (gradient 30-90% CH3CN in H2O) and lyophilization from CH- 3CN/H2O. Purity (HPLC): >99%; 1H NMR (400 MHZ, CDCl3): δ ppm 2.74 (s, 3 H), 2.90 (t, J=6.93 Hz, 2 H), 3.65 (q, J=6.05 Hz, 2 H), 5.59 (t, J=5.86Hz, 1 H), 6.51 (s, 2 H), 6.99- 7.06 (m, 2 H), 7.17-7.23 (m, 2 H), 7.45 (s, 1 H). MS (ESI) (M+H)+ = 398. Anal. Calcd for C16Hi4F3N3O2S : C5 52.03; H5 3.82; N, 11.38. Found: C, 51.80; H, 3.64; N, 11.63. 5
Compound 19 : 3-amino-iV-(2-cyclohexylethyl)-6-methyl-4-(trifluoromethyl)thieno[253- £]pyridine-2-carboxamide
Following a modified version of General Procedure 1 employing additional DIPEA5 3- amino-6-methyl-4-(trifluoromethyl)thieno[2,3-έ]pyridine-2-carboxylic acid (0.0751 g, 0.27 Q mmol), HATU (0.114 g, 0.30 mmol), DIPEA (0.14 mL, 0.80 mmol) and 2-cyclohexyletha- namine hydrochloride (0.0442 g, 0.27 mmol) were combined. The title compound was obtained as a yellow solid (0.0753 g, 72%) following purification by reverse phase HPLC (gradient 60-100% CH3CN in H2O) and lyophilization from CH3CN/H2O. Purity (HPLC): >99%; 1H-NMR (400 MHz, CDCl3): δ ppm 0.87 - 1.03 (m, 2 H), 1.11 - 1.26 (m, 3 H), 1.27 - 1.43 (m, 1 H), 1.47 - 1.54 (m, 2 H), 1.60 - 1.82 (m, 5 H), 2.73 (s, 3 H), 3.40 - 3.50 (m, 2 H), 5.51 (t, J=5.5 Hz, 1 H), 6.48 (s, 2 H), 7.44 (s, 1 H). MS (ESI) (M+H)+ = 386. Anal. Calcd for C18H22N3OSF3: C, 56.09; H, 5.75; N, 10.90. Found: C, 55.92; H, 5.68; N, 10.67.
Compound 20: 3-amino-6-methyl-N-(trans-4-methylcyclohexyl)-4-(trifluoro- methyl)thieno[2,3-ό]pyridine-2-carboxamide Following General Procedure 1, 3-atiiino-6-memyl-4-(trifluoromemyl)thieno[2,3-
6]pyridine-2-carboxylic acid (0.150 g, 0.54 mmol), HATU (0.310 g, 0.81 mmol), DIPEA (0.24 mL, 1.38 mmol), and trans-4-methyl-cyclohexylamine HCl (0.12 g, 0.80 mmol) were combined. The title compound was obtained as a yellow solid (0.072 g, 36%) following purification by column chromatography (30% ethyl acetate in hexanes). Purity (HPLC): >99%; 1H-NMR (400 MHz, CD3OD): δ ppm 0.90 (d, J=6.4 Hz, 3 H), 0.97 - 1.15 (m, 2 H)5 1.26 - 1.47 (m, 3 H), 1.67 - 1.82 (m, 2 H), 1.84 - 1.95 (m, 2 H), 2.69 (s, 3 H), 3.71 - 3.86 (m, IH), 7.64 (s, 1 H). MS (ESI) (M+H)+ = 372. Anal. Calcd for C17H20F3N3OS x 0.1H2O x 0.1HC1: C, 54.18; H, 5.43; N, 11.15. Found: C, 54.32; H, 5.36; N, 11.00. Compound 21: 6-methyl-3-(metliylamino)-N-(2-phenylethyl)-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide
To a solution of Compound 11 (0.120 g, 0.31 mmol) in methanol (5 mL) was added formaldehyde (37% in water, 70 μL, 0.95 mmol). The reaction was stirred overnight at room temperature. The next day, decaborane was added and the reaction was stirred for 2 hours and then concentrated in vacuo. The residue was taken up in dichloromethane and washed with 2 M NaOH. The aqueous layer was extracted with two portions of dichloromethane and the combined organic phases were dried over MgSO4, filtered and concentrated to give a 1:1 mixture of Compound 21 and Compound 22. The compounds were separated by reverse phase HPLC (40-90% CH3CN in H2O). The title compound was obtained as a yellow gum (0.049 g, 40%) following lyophilization from CH3CN/H2O. Purity (HPLC): >94%; 1H NMR (400 MHZ, CDCl3): δ ppm 2.50 (s, 3 H), 2.74 (s, 3 H), 2.99 (t, J=6.93 Hz, 2 H), 3.78 - 3.87 (m, 2 H), 7.22 - 7.38 (m, 5 H), 7.47 (s, 1 H), 9.07 (t, J=5.47 Hz, 1 H). MS (ESI) (MH-H)+ = 394. Anal. Calcd for C19H18F3N3OS + 0.35 TFA has C5 54.60; H, 4.27; N, 9.70. Found: C, 54.66; H, 4.14; N, 9.56.
Compound 22: 3-(dimethylamino)-6-methyl-iV-(2-phenyletliyl)-4-(trifluoro- methyl)mieno[2,3-Z?]pyridine-2-carboxamide
Isolated from the reaction mixture of Compound 21, the title compound was obtained as a yellow solid (0.051 g, 40%) following purification by reverse phase HPLC (40-90% CH3CN in H2O) and lyophilization from CH3CN/H2O. Purity (HPLC): >99%; 1H NMR (400 MHZ3 CDCl3): δ ppm 2.68 (s, 6 H), 2.72 (s, 3 H), 2.98 (t, J=6.84 Hz, 2 H), 3.81 (q, J=6.64 Hz, 2 H), 6.82 (br s, 1 H), 7.22 - 7.29 (m, 3 H), 7.31 - 7.37 (m, 2 H), 7.49 (s, 1 H). MS (ESI) (M+H)+ = 408. Anal. Calcd for C20H20F3N3OS has C, 58.96; H, 4.95; N, 10.31. Found: C, 58.78; H, 4.99; N, 10.54.
Intermediate 5: 4-(trifluoromethyl)nicotinonitrile 1 -oxide 4-(Trifluoromethyl)nicotinonitrile (10.0 g, 58.1 mmol) was dissolved in dichloromethane (400 mL) and 30% hydrogen peroxide (11.9 mL, 116 mmol) was added. The solution was cooled to 0 °C and trifluoroacetic anhydride (16.4 mL, 116 mmol) was slowly added via a dropping funnel. The reaction was warmed to 40 °C and stirred overnight. After cooling^ to room temperature, saturated aqueous Na2S2O3 was added and the solution was poured into a separatory funnel containing 1 M HCl. The layers were separated and the organic layer was washed with saturated aqueous sodium bicarbonate, dried over Na2SO4, filtered and concentrated to give the title compound of an off-white solid (10.5 g, 96%). 1H NMR (400 MHz, CDCl3): δ ppm 7.65 (d, J=7.03 Hz, 1 H), 8.37 - 8.40 (m, 1 H), 8.47 - 8.49 (m, I H).
Intermediate 6: 2-chloro-4-(trifluoromethyl)nicotinonitrile
A mixture of 4-(trifluoromethyl)nicotinonitrile 1-oxide (10.5 g, 55.8 mmol) and POCl3 (51 mL, 558 mmol) was heated at 110 °C for 5 hours. After evaporation of excess POCl3, the residue was taken up in dichloromethane and washed successively with 5% K2CO3 and water. The organic phase was then dried over Na2SO4, filtered and concentrated to give a mixture of the title compound and 6-chloro-4-(trifluoromethyl)nicotinonitrile. 1H NMR analysis of the crude material showed that the title compound was the major isomer (7:3 2- chloro:6-chloro). The isomers were separated by flash chromatography. The 6-chloro isomer was eluted first with 9:1 hexanes:Et3N. Eluting with dichloromethane gave the title compound as an orange oil (4.50 g, 38%). 1H NMR (400 MHz, CDCl3): δ ppm 7.67 (d, J=5.08 Hz, 1 H), 8.81 (d, J=5.08 Hz, 1 H).
Intermediate 7: 3-amino-4-(trifluoromethyl)thieno[2,3-δ]pyridine-2-carboxylic acid A solution of 2-chloro-4-(trifluoromethyl)nicotinonitrile (2.00 g, 9.68 mmol) in ethanol (10 mL) was added to a stirred solution of ethyl 2-mercaptoacetate and sodium ethoxide in ethanol (10 mL). The reaction was heated to reflux for 5 hours, and additional sodium ethoxide was added, if necessary, until the cyclization was complete as determined by 1H NMR. The reaction mixture was poured into a flask containing ice/H2O and was acidified with 1 M HCl to pH 2. The resulting solid was collected by vacuum filtration to give the title compound as a yellow solid (2.10 g, 83%). 1H NMR (400 MHz, CD3OD): δ ppm (d, J=4.88 Hz, 1 H), 8.83 (d, J-4.88 Hz, 1 H).
Compound 23 : 3-amino-N-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide
Following General Procedure 1, 3-amino-4-(trifluoromethyl)thieno[2,3-δ]pyridine-2-car- boxylic acid (0.030 g, 0.11 mmol), HATU (0.048. g, 0.13 mmol), DIPEA (28 μL, 0.16 mmol), and (2-phenylethyl)amine (13 μL, 0.16 mmol) were combined. The title compound was obtained as a yellow solid (27.7 mg, 69%) following purification by reverse phase HPLC (gradient 20-90% CH3CN in H2O) and lyophilization from CH3CN/H2O. Purity (HPLC): >99%; 1H NMR (400 MHZ, CDCl3): δ ppm 2.94 (t, J-6.93 Hz, 2 H), 3.66 - 3.74 (m, 2 H), 5.65 (t, J=4.69 Hz, 1 H), 6.53 (s, 2 H) 7.22 - 7.30 (m, 3 H), 7.31 - 7.39 (m, 2 H), 7.59 (d, J=4.88 Hz, 1 H), 8.77 (d, J=4.69 Hz, 1 H). MS (ESI) (M+H)+ = 366. Anal. Calcd for C17H14F3N3OS x 0.35 TFA: C, 52.46; H, 3.57; N, 10.37. Found: C, 52.59; H, 3.43; N, 10.47.
Compound 24: 3-amino-N-[2-(4-methylphenyl)ethyl]-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide Following General Procedure 1, 3-amino-4-(trifluoromethyl)thieno[233-6]ρyridine-2-car- boxylic acid (0.030 g, 0.11 mmol), HATU (0.048 g, 0.13 mmol), DIPEA (28 μL, 0.16 mmol), and [2-(4-methylphenyl)ethyl]amine (14 μL, 0.16 mmol) were combined. The title compound was obtained as a yellow solid (30.0 mg, 72%) following purification by re-
5 verse phase HPLC (gradient 20-90% CH3CN in H2O) and lyophilization from CH3CN/H- 2O. Purity (HPLC): >99%; 1H NMR (400 MHZ, CDCl3): δ ppm 2.34 (s, 3 H), 2.89 (t, J=6.93 Hz, 2 H), 3.63 - 3.70 (m, 2 H), 5.64 (s, 1 H), 6.52 (s, 2 H), 7.11 - 7.18 (m, 4 H), 7.59 (d, J=4.88 Hz3 1 H), 8.77 (d, J=4.69 Hz, 1 H). MS (ESI) (M+H)+ = 380. Anal. Calcd for C18Hi6F3N3OS + 0.05 H2O + 0.1 TFA: C, 55.81; H, 4.17; N, 10.73. Found: C, 55.40; o H, 3.75; N, 11.04.
Compound 25: 3-amino-N-[2-(3-fluorophenyl)ethyl]-4-(trifluorometbyl)thieno[2,3- b]pyridine-2-carboxamide
Following General Procedure 1, 3-amino-4-(trifluoromethyl)thieno[2,3-Z)3pyridine-2-car- 5 boxylic acid (0.030 g, 0.11 mmol), HATU (0.048 g, 0.13 mmol), DIPEA (28 μL: 0.16 mmol), and [2-(3-fluorophenyl)ethyl]amine (14 μL, 0.16 mmol) were combined. The title compound was obtained as a yellow solid (23.7 mg, 56%) following purification by re-- verse phase HPLC (gradient 20-90% CH3CN in H2O) and lyophilization from CH3CN/H-
2O. Purity (HPLC): >99%; 1H NMR (400 MHZ, CDCl3): δ ppm 2.94 (t, J-7.03 Hz, 2 H), 0 3.66 - 3.73 (m, 2 H), 5.65 (t, J=5.08 Hz, 1 H), 6.54 (s, 2 H)3 6.92 - 6.99 (m, 2 H), 7.03 (d,
J=7.62 Hz, 1 H), 7.27 - 7.34 (m, 1 H), 7.60 (d, J=4.88 Hz, 1 H), 8.77 (d, J=4.69 Hz3 1 H).
MS (ESI) (M+H)+ = 384. Anal. Calcd for CnH13F4N3OS + 0.1 H2O + 0.25 TFA: C3
51.81; H3 3.28; N3 10.16. Found: C3 51.12; H3 3.11; N3 9.81.
S Table 1. Compounds prepared according to general General Procedure 2.
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Pharmacology
1. hVRl FLIPR (Fluorometric Image Plate Reader) screening assay
Transfected CHO cells, stably expessing hVRl (15,000 cells/well) are seeded in 50 ul media in a black clear bottom 384 plate (Greiner) and grown in a humidified incubator (37°C, 2% CO2), 24-30 hours prior to experiment.
Subsequently, the media is removed from the cell plate by inversion and 2 μM Fluo-4 is added using a multidrop (Labsy stems). Following the 40 minutes dye incubation in the dark at 37°C and 2% CO2, the extracellular dye present is washed away using an EMBLA (Scatron), leaving the cells in 40ul of assay buffer (1 X BBSS, 10 mM D-Glucose, 1 mM CaCl2, 10 mM HEPES, 10 X 7.5% NaHCO3 and 2.5 mM Probenecid).
FLIPR assay - IC50 determination protocol
For ICso determinations the fluorescence is read using FLlPR filter 1 (em 520-545 nM). A cellular baseline recording is taken for 30 seconds, followed by a 20 μl addition of 10, titrated half-log concentrations of the test compound, yielding cellular concentration ranging from 3 μM to 0.1 nM. Data is collected every 2 seconds for a further 5 minutes prior to the addition of a VRl agonist solution: either 50 nM solution of capsaicin or MES (2-[N-mor- pholino] ethanesulfonic acid) buffer (pH 5.2), by the FLIPR pipettor. The FLIPR continues to collect data for a further 4 minutes. Compounds having antagonistic properties against the hVRl will inhibit the increase in intracellular calcium in response to the capsaicin addition. This consequently leading to a reduction in fluorescence signal and providing a reduced fluorescence reading, compared with no compound, buffer controls. Data is exported by the FLIPR program as a sum of fluorescence calculated under the curve upon the addition of capsaicin. Maximum inhibition, Hill slope and IC5O data for each compound are generated.
List of abbreviations VRl vanilloid receptor 1 IBS ■ irritable bowel syndrome IBD inflammatory bowel disease
GERD gastroesophageal reflux disease HEPES 4-(2-Hydroxyethyl)piperazine-l-ethanesulfonic acid
EGTA Ethylene glycol-bis(2-aminoethylether)-iV;iV;iV',iV"-tetraacetic acid
EMBLA Skatron, Plate Cell Washer, from Molecular Devices company
HBSS Hank's Balanced Salt Solution
MES (2-[N-Moφhholino]ethanesulfonic acid) Hydrate, Sigma cat# M-5287
NUT Nutrient mixture F- 12, medium for culturing cells
MEM Minimal Eagle Medium
Results
Typical ΪC50 values as measured in the assays described above are 1 μM or less. In one aspect of the invention the IC50 is below 750 nM. In another aspect of the invention the IC50 is below 150 nM. Iu a further aspect of the invention the IC50 is below 10 nM.
Table 2. Specimen results from the hVRl FLIPR
Figure imgf000044_0001

Claims

1. A compound of formula I
Figure imgf000045_0001
wherein:
R1 and R2 are independently selected from H3 NO2, NH2, halo, N(Ci.3aIkyl)2, C1-3alkyl, C2.
3alkenyl, C2-3alkynyl, C1-3haloalkyl, C1-3haloalkylO5 hydroxyC1-3alkyl, Ci-3alkylOCo.3alkyl,
C1-3alkylSC0-3alkyl and C1-3alkylNC0-3alkyl;
Y is NH2, NH(R3), N(R3)2, OH, OR3 or NO2; R3 is C1-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci-3haloalkyl, Q.ahalbalkylO, hydroxyC1-3alkyl,
C1-3alkylOC0-3alkyl, C1-3alkylSC0-3alkyl or C1-3alkyINC0_3alkyJ.;
R9 is H, Ci-βalkyl, R6OC0-6alkyl, or C5-10arylC0-6alkyl;
X is bond, CR6R7, NR6R7 or O; p is O, 1, 2, or 3; R4 is bond, H5 Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6haloalkyl, C1-6haloalkylO, C5- loarylCo-6alkyl, C5-10heteroarylCo-6alkyl, C3-15cycloalkylC0-6alkyl, C3-15heterocycloalkylC0- βalkyl, R6OC0-6alkyl, R6SC0-6alkyl or R6NC0-6alkyl, COOR6, R6COR7, R6CO2,
R6CONR7R8, R6NR7COCo-6alkyl, R6SO2R7 or R6SOR7R8;
R5 is H, OH, oxy, NO2, NH2, halo, N(C1-3alkyl)2, C1-3alkyl, C2-3alkenyl, C2-3alkynyl, Ci- 3haloalkyl, C1-3haloalkylO, hydroxy C 1-3alkyl, R6OC0-6alkyl, R6SC0-6alkyl, R6NC0-6alkyl,
C5-ioarylOC0-6alkyl, C5-i0heteroarylOCo-6alkyl, C3-10cycloalkylOC0-6alkyl, R6COO,
R6COR7, R6CO2, R6CONR7R8, R6NR7COC0-6alkyl or R6SO2R7 or R6SOR7R8;
R6, R7 and R8 are independently selected from H, C1-6alkyl and Cs-warylCo-βalkyl; or X and R6 form a 4, 5, 6 or 7 membered ring; and n is 0, 1, 2, 3, 4, 5, 6 or 7; or salts, solvates or solvated salts thereof.
2. The compound according to claim 1, wherin p is I, 2, or 3, with the proviso that is not 3- amino-6-methyl-4-trifluoromethyl-thieno[2,3 -b]pyridine-2-carboxylic acid ben∑ylamide. 3. The compounds selected from the group consisting of
3-amino-6-methyl-iV-(3-phenylpropyl)-4-(trifluoromethyl)thieno[2,3-ό]pyridine-2-carbox- amide, 3-aim'no-6-methyl-iV'-[2-(4-methylphenyl)ethyl]-4-(trifluoromethyl)thieno[2,3-6]pyridine-
2-carboxamide,
3-amino-6-methyl-7V-[2-(2-methylphenyl)ethyl]-4-(trifluoromethyl)thieno[2,3-δ]pyridine-
2-carboxamide,
3-amino-6-methyl-iV-(2-phenylpropyl)-4-(trifluoromethyl)thieno[2,3-ό]pyridine-2-carbox- amide,
■ 3-amino-N,6-dimethyl-N-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-6]pyridine-2-car-- boxamide,
3-amino~iV-[2-(2-methoxyphenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- ό]pyridine-2-carboxamide, 3-amino-N-(2,2-diphenylethyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-5]pyridine-2-car- boxamide,
3-amino-N-[2-(3-fluorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-Z7]pyridine-2- carboxamide,
3-amino-iV-[2-(3,4-dichlorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- Z>]pyridine-2-carboxamide,
3-amino-6-methyl-4-(trifluoromethyl)-iV-{2-[3-(trifluoromethyl)phenyl]ethyl}thieno[2,3-
Z?]pyridine-2-carboxamide,
3-amino-6-methyl-Ν-{2-[3-(methyloxy)phenyl]ethyl}-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide, 3-amino-6-methyl-N-[2-(2-thienyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-car- boxamide,
3-amino-N-[2-(2,6-dichlorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-[2-(2-fluorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-amino-6-methyl-N-[2-(phenyloxy)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-car- boxamide, 3-amino-N-(2,3-dihydro-l,4-benzodioxin-2-ylmethyl)-6-methyl-4-(trifluoro- methyl)thieno [2,3 -b]pyridine-2~carboxamide,
3-amino-N-{2-[4-(ethyloxy)phenyl]ethyl}-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide, 5 3-amino-6-methyl-N-(4-methylcyclohexyl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-amino-6-metb.yl-N-{2-[2-(phenyloxy)plienyl]ethyl}-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-6-methyl-N-{[5-methyl-2-(1xifluoromethyl)-3-furanyl]methyl}-4-(trifluoro- i o methyl)thieno [2,3 -b]pyridine-2-carboxamide.,
1 , 1 -dimethylethyl 4-( { [3 -aminϋ~6-methyl-4: (trifluoromethyl)thieno[2,3 -b]pyridin-2- yl]carbonyl}amino)-l-piperidinecarboxylate,
3-ammo-N-{[3-fluoro-5-(trifluorometb.yl)phenyl]methyl}-6--methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide, is 3-amino-6-methyl-4-(trifluoromethyl)-N-{[3-(trifluoromethyl)phenyl]methyl}thieno[2,3- b]pyridine-2-carboxamide,
3 -amino-N-(3 ,3 -dimethy lbutyl)-6-methyl-4-(trifluoromethyl)thieno [2,3 -b]pyridine-2-car- boxamide,
3-amino-6-methyl-4-(trifluoromethyl)-N-({3-[(trifluoro- 0 methyl)oxy]phenyl}metb.yl)thieno[2,3-b]pyridine-2-carboxamide,
3 -amino-N- {2-[4-( 1 , 1 -dimethylethyl)phenyl]ethyl} -6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-6-methyl-N-{3-[metliyl(phenyl)amino]propyl}-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide, 5 3 -amino-N- [(3 , 5-dimethylphenyl)methy 1] -6-methyl-4-(trifluoromethyl)thieno [2,3 - b]pyridine-2-carboxamide,
3-amino-N-(cyclohexylmethyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-car- boxamide,
3-amino-N-butyl-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide, 0 3-amino-N-[2-(2,4-dichlorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)tb.ieno[233- b]ρyridine-2-carboxamide,
3-amino-N-cyclohexyl-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxaniide, 3-ainino-N-[(5-fluoro-2-me1hylphenyl)methyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-[l-(4-fluorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)tliieno[2,3-b]pyridme-2- carboxamide, 3-amino-6-metb.yl-N-(2-methylpropyl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carbox- amide,
3-amino-N-[(6-fluoro-4H-l,3-benzodioxin-8-yl)methyl]-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N,6-dimethyl-4-(trifluoromethyl)-N-{[3-(trifluoro- methyl)phenyl]methyl}thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N-(2,3-dihydro- 1 -benzofuran-5-ylmethyl)-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-ammθ"6-methyl-N-[2-(2-pyridinyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide, 3-amino-6-methyl-N-[2-(4-pyridinyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-amino-6-methyl-N-[(2S)-2-phenylpropyl]-4-(trifluorometb.yl)thieno[2,3-b]pyridine-2- carboxamide,
3-amirjo-6-methyl-N-[(2R)-2-phenylpropyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-amino-N-[(2i?)-2-hydroxy-2-phenylethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- έ]pyridine-2-carboxamide,
3-amino-iV-[(25)-2-hydroxy-2-phenylethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-
Z?]pyridine-2-carboxamide, 3-amino-N-(2-hydroxy-2-phenylpropyl)-6-methyl-4-(trifluoromethyl)thieno[2,3- έ]pyridine-2-carboxamide,
3-amino-N-[2-(2-furyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carbox- amide,
3-ammo-N-[2-(4-fluorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridme-2- carboxamide,
3-ammo-iV-(2-cyclohexylethyl)-6-metliyl-4-(trifluoromethyl)thieno[2,3-Zj]pyridme-2-car- boxamide, 3-amino-6-methyl-N-(trans-4-methylcyclohexyl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-
2-carboxamide,
6-methyl-3-(methylainino)-N-(2-phenylethyl)-4-(trifluoroniethyl)thieno[2,3-b]pyridine-2- carboxamide, 5 3-(dimethylamino)-6-methyl-N-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-ό]pyridine-
2-carboxamide,
3-amino-N-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N-[2-(4-methylpb.eiiyl)ethyl]-4-(trifluoroniethyl)thieno[2,3-b]pyridine-2-carbox- amide, and i o 3 -amino-N-[2-(3 -fluorophenyl)ethyl]-4-(trifmoromethyl)thieno [2,3 -b]pyridine-2-carbox- amide, or salts, solvates or solvated salts thereof.
4. The compounds selected from the group consisting of is 3-amino-6-methyl-iV-(3-phenylpropyl)τ4-(trifluoromethyl)thieno[2,3-δ]pyridine-2-carbox- amide,
3-amino-6-methyl-iV-[2-(4-methylphenyl)ethyl]-4-(trifluoromethyl)thieno[2,3-δ]pyridine-
2-carboxamide,
3-amino-6-methyl-N-[2-(2-methylphenyl)ethyl]-4~(trifluoromethyl)thieno[2,3-Z>]pyridine- 0 2-carboxamide,
3-amino-6-methyl-iV-(2-phenylpropyl)-4-(trifluoromethyl)thieno[2:,3-δ]pyridine-2-carbox- amide,
3-amino-N,6-dimethyl-iV-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-Z>]pyridine-2-car- boxamide, 5 3-amino-iV-[2-(2-methoxyphenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-
Z7]pyridine-2-carboxamide,
3-amino-Λr-(2,2-diphenylethyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-έ]pyridine-2-car- boxamide,
3-amino-iV-[2-(3-fluorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[253-Z?]pyridine-2- 0 carboxamide,
3-amino-iV-[2-(3,4-dichlorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- ό]pyridine-2-carboxamide, 3-amino-6-methyl-4-(trifluoromethyl)-N-{2-[3-(trifluoromethyl)phenyl]ethyl}tliieno[2,3- έ]pyridine-2-carboxamide, and or salts, solvates or solvated salts thereof.
5. The compounds selected from the group consisting of
3-amino-6-methyl-N-{2-[3-(methyloxy)phenyl]ethyl}-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-ammo-6-methyl-N-[2-(2-thienyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-car- boxamide, 3-amino-N-[2-(2,6-dichlorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-[2-(2-fluorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[253-b]pyridme-2-- " carboxamide,
3-amino-6-methyl-N-[2-(phenyloxy)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-car" boxamide,
3-amino-N-(2,3-dihydro-l,4-benzodioxin-2-ylmethyl)-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N-{2-[4-(ethyloxy)phenyl]ethyl}-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide, 3-amino-6-methyl-N-(4-methylcyclohexyl)-4-(trifluoromethyl)thieno[2,3-b]pyridme-2- carboxamide,
3-amino-6-methyl-N-{2-[2-(phenyloxy)phenyl]ethyl}-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-6-methyl-N-{[5-methyl-2-(trifluoromethyl)-3-furanyl]methyl}-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide, l,l-dimethylethyl 4-({[3-ammo-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridin-2- yl]carbonyl}amino)-l-piperidinecarboxylate,
3-amino-N-{[3-fluoro-5-(trifluoromethyl)phenyl]methyl}-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide, 3-amino-6-methyl-4-(trifluoromethyl)-N-{[3-(trifluoromethyl)phenyl]methyl}thieno[2,3- b]pyridine-2-carboxamide3 3-amino-N-(3,3-dimethylbutyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-car- boxamide,
3-amino-6-methyl-4-(trifluoromethyl)-N-({3-[(trifluoro- methyl)oxy]phenyl}methyl)thieno[2,3-b]pyridine-2-carboxamide, 3-amino-N- {2-[4-(l , 1 -dimethylethyl)phenyl]ethyl} -6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-6-methyl-N-{3-[methyl(phenyl)amήio]propyl}-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-[(3,5-dimethylphenyl)methyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide;
3-amino-N-(cyclohexylmethyl)-6-mcthyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-car- boxamide,
3-amino-N-butyl-6-methyl-4-(triflu6iOmethyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N-[2-(2,4-dichlorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-cyclohexyl-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxaiiiide,
3-amino-N-[(5-fluoro-2-methylphenyl)methyl]-6-methyl-4-(trifluoromethyl)thieno[2,3- b]pyridine-2-carboxamide,
3-amino-N-[l-(4-fluorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridme-2- carboxamide,
3-aiiiino-6-methyl-N-(2-methylpropyl)-4-(trifluoroniethyl)thieno[2,3-b]pyridine-2-carbox- amide, ,
3 -amino-N- [(6-fluoro-4H- 1 ,3 -benzodioxin- 8-yl)methy 1] -6-methy l-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide, 3-amino-N,6-dimethyl-4-(trifluoromethyl)-N-{[3-(trifluoro- methyl)phenyl]methyl}thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N-(2,3-dihydro-l-benzofuran-5-ylmethyl)-6-methyl-4-(trifluoro- methyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-6-methyl-N-[2-(2-pyridinyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide, and
3-ammo-6-methyl-N-[2-(4-pyridinyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide, or salts, solvates or solvated salts thereof.
6. The compounds selected from the group consisting of
3-amino-6-methyl-iV-[(2S)-2-phenylpropyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- 5 carboxamide,
3-amino-6-methyl-iV-[(2R)-2-phenylpropyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-amino-iV-[(2i?)-2-hydroxy-2-phenylethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-
6]pyridine-2-carboxamide, o 3-amino-iV-[(25)-2-hydroxy-2-phenylethyl]-6-methyl-4-(trifluoromethyJ)thiετi.o[2:,3- ό]pyridine-2-carboxamide,
3-amino-N-(2-hydroxy-2-phenylpropyl)-6-methyl-4-(trifluoromethyl)thieno[2,3- έ]pyridine-2-carboxamide,
3-amino-N-[2-(2-furyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridiπe-2-carbox- s amide,
3-ammo-N-[2-(4-fluorophenyl)ethyl]-6-methyl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-amino-iV-(2-cyclohexylethyl)-6-methyl-4-(trifluoromethyl)thieno[2,3-έ]pyridine-2-car- boxamide, Q 3-amino-6-methyl-N-(trans-4-methylcyclohexyl)-4-(trifluoromethyl)thieno[2,3-δ]pyridine-
2-carboxamide,
6-methyl-3-(methylamino)-N-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2- carboxamide,
3-(dimethylamino)-6-methyl-iV-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-6]pyridine- 5 2-carboxamide,
3-amino-N-(2-phenylethyl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide,
3-amino-N-[2-(4-methylphenyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carbox- amide, and
3-amino-N-[2-(3-fluorophenyl)ethyl]-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carbox- 0 amide, or salts, solvates or solvated salts thereof.
7. The compound according to any one of claims 1 to 6, for use in therapy.
8. Use of the compound according to any one of claims 1 to 6, in treatment of VRl mediated disorders.
9. The use according to claim 8 for treatment of acute and chronic pain, acute and chronic neuropathic pain and acute and chronic inflammatory pain.
10. The use according to claim 8 for treatment of respiratory diseases.
11. A method of treatment of VRl mediated disorders and for treatment of acute and chronic pain, acute and chronic neuropathic pain and acute and chronic inflammatory pain, and respiratory diseases, comprising administrering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compound of formula I, according to any one of claims 1 to 6.
12. A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound of formula I, according to any one of claims 1 to 6, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert car- riers.
13. The pharmaceutical formulation according to claim 12, for use in the treatment of VRl mediated disorders and for treatment of acute and chronic pain, acute and chronic neuropathic pain and acute and chronic inflammatory pain, and respiratory diseases.
14. Use of 3-amino-6-methyl-4-(trifluoromethyl)thieno[2,3-Z>]pyridine-2-carboxylic acid as intermediate in the preparation of compounds according to any one of claims 1 to 6.
15. The compounds 4-(trifluoromethyl)nicotinonitrile 1 -oxide,
2-chloro-4-(trifluoromethyl)nicotinonitrile5 and 3-amino-4-(trifluoromethyl)thieno[2,3-ό]pyridine-2-carboxylic acid.
16. Use of the compound according to claim 15 as intermediate in the preparation of compounds according to any one of claims 1 to 6.
PCT/SE2005/002020 2004-12-23 2005-12-22 New compounds WO2006068618A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/721,637 US20080306107A1 (en) 2004-12-23 2005-12-22 Compounds
JP2007548159A JP2008525434A (en) 2004-12-23 2005-12-22 New compounds
EP05821044A EP1833834A1 (en) 2004-12-23 2005-12-22 New compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0403171-2 2004-12-23
SE0403171A SE0403171D0 (en) 2004-12-23 2004-12-23 New compounds

Publications (1)

Publication Number Publication Date
WO2006068618A1 true WO2006068618A1 (en) 2006-06-29

Family

ID=34102119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2005/002020 WO2006068618A1 (en) 2004-12-23 2005-12-22 New compounds

Country Status (6)

Country Link
US (1) US20080306107A1 (en)
EP (1) EP1833834A1 (en)
JP (1) JP2008525434A (en)
CN (1) CN101128470A (en)
SE (1) SE0403171D0 (en)
WO (1) WO2006068618A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084050A2 (en) 2009-01-13 2010-07-29 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
WO2013187462A1 (en) 2012-06-14 2013-12-19 第一三共株式会社 Piperidinylpyrazolopyridine derivative
EP2928470A4 (en) * 2012-12-07 2015-12-16 Siga Technologies Inc Thienopyridine derivatives for the treatment and prevention of dengue virus infections
US9301949B2 (en) 2009-02-27 2016-04-05 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections
WO2017139778A1 (en) * 2016-02-12 2017-08-17 Forma Therapeutics, Inc. Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
WO2018222795A1 (en) 2017-06-01 2018-12-06 Bristol-Myers Squibb Company Substituted nitrogen containing compounds
US10889592B2 (en) 2016-02-12 2021-01-12 Valo Early Discovery, Inc. Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
WO2022035806A1 (en) * 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
EP3954694A4 (en) * 2019-05-09 2022-08-24 Chaser Therapeutics, Inc. Ubiquitin-specific protease inhibitors, and preparation method therefor and application thereof
US11524966B1 (en) 2017-08-11 2022-12-13 Valo Health, Inc. Carboxamides as ubiquitin-specific protease inhibitors

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948438A4 (en) * 2013-01-23 2016-10-05 Univ Chicago Methods and compositions for inhibiting human copper trafficking proteins atox1 and ccs
ES2789756T3 (en) 2015-12-23 2020-10-26 Merck Sharp & Dohme Allosteric modulators of 6,7-dihydro-5H-pyrrolo [3,4-b] pyridin-5-one of the muscarinic acetylcholine receptor M4
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of m4 muscarinic acetylcholine receptor
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5-(pyridin-3-yl)oxazole allosteric modulators of m4 muscarinic acetylcholine receptor
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of m4 muscarinic acetylcholine receptor

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239887A (en) * 1979-10-31 1980-12-16 Usv Pharmaceutical Corporation Pyridothienotriazines
DD247002A1 (en) * 1986-02-26 1987-06-24 Univ Leipzig PROCESS FOR PREPARING SUBSTITUTED N-ALKYL (OR ARYL) - (3-AMINO-THIENO / 2,3-B / PYRIDINE) -2-CARBONATEAMIDE
WO1992003427A1 (en) * 1990-08-17 1992-03-05 Yoshitomi Pharmaceutical Industries, Ltd. Ketone compound and remedy for osteoporosis
US5118680A (en) * 1989-06-20 1992-06-02 Bayer Aktiengesellschaft Combating endoparasites with 3-hydroxybenzothiophenes
WO1993013664A2 (en) * 1992-01-11 1993-07-22 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
WO1996016954A1 (en) * 1994-12-02 1996-06-06 Agrevo Uk Limited Derivatives of anthranilic acid useful as fungicides
EP1310488A1 (en) * 2000-08-09 2003-05-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
US20040180922A1 (en) * 2002-06-06 2004-09-16 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
RU2241002C1 (en) * 2003-07-24 2004-11-27 Кубанский государственный технологический университет 1,2,3,4-tetrahydropirido[3',2':4,5]thieno-[3,2-d]-pyrimidin-4-ones as antidotes of herbicide with hormonal effect of 2,4-dichlorophenoxyacetic acid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3506767A (en) * 1965-08-06 1970-04-14 Geigy Chem Corp Benzimidazole compositions and methods of use
US3711608A (en) * 1971-04-13 1973-01-16 Merck & Co Inc The treatment of pain, fever and inflammation with benzimidazoles
DE4237617A1 (en) * 1992-11-06 1994-05-11 Bayer Ag Use of substituted benzimidazoles
AU2003252715B2 (en) * 2002-07-30 2009-06-04 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
AR045979A1 (en) * 2003-04-28 2005-11-23 Astrazeneca Ab HETEROCICLIC AMIDAS

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239887A (en) * 1979-10-31 1980-12-16 Usv Pharmaceutical Corporation Pyridothienotriazines
DD247002A1 (en) * 1986-02-26 1987-06-24 Univ Leipzig PROCESS FOR PREPARING SUBSTITUTED N-ALKYL (OR ARYL) - (3-AMINO-THIENO / 2,3-B / PYRIDINE) -2-CARBONATEAMIDE
US5118680A (en) * 1989-06-20 1992-06-02 Bayer Aktiengesellschaft Combating endoparasites with 3-hydroxybenzothiophenes
WO1992003427A1 (en) * 1990-08-17 1992-03-05 Yoshitomi Pharmaceutical Industries, Ltd. Ketone compound and remedy for osteoporosis
WO1993013664A2 (en) * 1992-01-11 1993-07-22 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
WO1996016954A1 (en) * 1994-12-02 1996-06-06 Agrevo Uk Limited Derivatives of anthranilic acid useful as fungicides
EP1310488A1 (en) * 2000-08-09 2003-05-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
US20040180922A1 (en) * 2002-06-06 2004-09-16 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
RU2241002C1 (en) * 2003-07-24 2004-11-27 Кубанский государственный технологический университет 1,2,3,4-tetrahydropirido[3',2':4,5]thieno-[3,2-d]-pyrimidin-4-ones as antidotes of herbicide with hormonal effect of 2,4-dichlorophenoxyacetic acid

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] KADUSHKIN A.V. ET AL: "Synthesis and biological characteristics of 4-(phenylamino)- and 4-(dimethylamino)-3-cyanopyridine-2-thiones and derived thieno(2,3-b)pyridines", XP002998716, accession no. STN International Database accession no. 1993:428032 *
DATABASE CAPLUS [online] YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.: "Preparation of furo- or thienopyridine derivatives for treatment of osteoporosis", XP002998714, accession no. STN International Database accession no. 1992:469849 *
DATABASE CAPLUS [online] YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.: "Thiopene derivatives", XP002998715, accession no. STN International Database accession no. 1976:421428 *
DATABASE REGISTRY [online] XP002998710, accession no. STN international Database accession no. 507447-02-1 *
DATABASE REGISTRY [online] XP002998711, accession no. STN International Database accession no. 340807-85-4 *
DATABASE REGISTRY [online] XP002998717, accession no. STN Database accession no. 610259-30-8 *
KHIMIKO-FARMATSEVTICHESKII ZHURNAL, vol. 26, no. 11-12, 1992, pages 62 - 66 *
NIKISHIN K.G. ET AL: "Regioselective synthesis and properties of 3-cyano-6-methyl-4-trifluoromethylpyridine-2(1H)-thione. Molecular and crystal structure of 3-cyano-2-ethylthio-6-methyl-4-trifluoromethylpyridine", RUSSIAN CHEMICAL BULLETIN, vol. 47, no. 3, March 1998 (1998-03-01), pages 465 - 468, XP002998713 *
SHETOPALOV A.M. ET AL: "Preparation of Trifluoromethylpyridine Libraries", J. COMB. CHEM., vol. 2, 2000, pages 24 - 28, XP002998712 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084050A2 (en) 2009-01-13 2010-07-29 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
US9301949B2 (en) 2009-02-27 2016-04-05 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2013187462A1 (en) 2012-06-14 2013-12-19 第一三共株式会社 Piperidinylpyrazolopyridine derivative
EP2928470A4 (en) * 2012-12-07 2015-12-16 Siga Technologies Inc Thienopyridine derivatives for the treatment and prevention of dengue virus infections
WO2017139778A1 (en) * 2016-02-12 2017-08-17 Forma Therapeutics, Inc. Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
US10889592B2 (en) 2016-02-12 2021-01-12 Valo Early Discovery, Inc. Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
US10913753B2 (en) 2016-02-12 2021-02-09 Valo Early Discovery, Inc. Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
US11325917B2 (en) 2016-02-12 2022-05-10 Valo Health, Inc. Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
WO2018222795A1 (en) 2017-06-01 2018-12-06 Bristol-Myers Squibb Company Substituted nitrogen containing compounds
EP3929194A1 (en) 2017-06-01 2021-12-29 Bristol-Myers Squibb Company Substituted nitrogen containing compounds
USRE49700E1 (en) 2017-06-01 2023-10-17 Bristol-Myers Squibb Company Substituted nitrogen containing compounds
US11524966B1 (en) 2017-08-11 2022-12-13 Valo Health, Inc. Carboxamides as ubiquitin-specific protease inhibitors
EP3954694A4 (en) * 2019-05-09 2022-08-24 Chaser Therapeutics, Inc. Ubiquitin-specific protease inhibitors, and preparation method therefor and application thereof
AU2020268932B2 (en) * 2019-05-09 2023-09-07 Chaser Therapeutics Inc. Ubiquitin-specific protease inhibitors, and preparation method therefor and application thereof
WO2022035806A1 (en) * 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28

Also Published As

Publication number Publication date
JP2008525434A (en) 2008-07-17
EP1833834A1 (en) 2007-09-19
CN101128470A (en) 2008-02-20
SE0403171D0 (en) 2004-12-23
US20080306107A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
WO2006068618A1 (en) New compounds
US5585385A (en) Heterocyclic compounds, their production and use as tachykinin reactor antagonists
JP5916700B2 (en) Amide compounds, compositions and uses thereof
JP5608655B2 (en) Modulator of P2X3 receptor activity
JP5201817B2 (en) Pharmaceutical composition
EP0807633B1 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
SK113299A3 (en) Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
AU2008293038A1 (en) Inhibitors of protein tyrosine kinase activity
AU2005300736A1 (en) Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
AU2005300734A1 (en) Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
JPH08337583A (en) Heterocyclic compound and its production
EP0977743A1 (en) Protease inhibitors
EP0900799B1 (en) Novel atropisomers of 2,3-disubstituted-(5,6)-heteroarylfused-pyrimidin-4-ones
JP4533148B2 (en) Imidazoquinoline derivatives as adenosine A3 receptor ligands
WO2006068593A1 (en) New benzothiazolesulfonamides
KR102002446B1 (en) Quinoline-5,8-dione derivatives for TGase inhibitor, and the pharmaceutical composition comprising the same
WO2006068592A1 (en) New benzothiazolecarboxamides
KR101412794B1 (en) New compound, the preparation thereof and the pharmaceutical composition comprising the same for anti-angiogenic drug
AU2006221037A1 (en) 1,3-thiazole-5-carboxamides useful as cancer chemotherapeutic agents
JPH0867678A (en) Heterocyclic amido compound, its production and treating agent
MXPA98007227A (en) New atropisomeros de (5,6) -heteroarilcondensado-pirimidin-4-onas 2,3 disustitui
CZ9902994A3 (en) Atropoisomers of 3-aryl-4(3H)-quinazolinones and their application as antagonizing agents of AMPA receptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 4582/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007548159

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005821044

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580048608.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005821044

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11721637

Country of ref document: US